1. Jump to: A B C D E F G H I J K L M N O P Q R S T U V W Y Z
  2. Acuff-Smith, K. D., George, M., Lorens, S. A. & Vorhees, C.V. (1992). Preliminary evidence for methamphetamine-induced behavioral and ocular effects in rat offspring following exposure during early organogenesis. Psychopharmacology, 109(3), 255–263.

  3. Addis, A., Moretti, M. E., Syed, F. A., Einarson, T. R. & Koren, G. (2001). Fetal effects of cocaine: an updated meta-analysis. Reproductive Toxicology, 15, 341–369.

  4. ADEC, (1999). Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy (4th ed.). Canberra: Publications Unit, Therapeutic Goods Administration.

  5. Adlaf, E. M., Paglia, A. & Ivis, F. J. (2000). Drug use among Ontario students, 1977–1999: Findings from the OSDUS (CAMH Research Doc. Series No. 5).Toronto: Centre for Addiction and Mental Health.

  6. Aggarwal, S. K., Williams, V., Levine, S. R., Cassin, B. J. & Garcia, J. H. (1996). Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases. Neurology, 46(6), 1741–1743.

  7. Albertson, T. E., Dawson, A., de Latorre, F., Hoffman, R. S., Hollander, J. E., Jaeger, A., Kerns, W. R., 2nd, Martin, T. G. & Ross, M. P. (2001).TOX-ACLS: toxicologic-oriented advanced cardiac life support. Annals of Emergency Medicine, 37(4 Suppl), S78–90.

  8. Alldredge, B. K., Lowenstein, D. H. & Simon, R. P. (1989). Seizures associated with recreational drug abuse. Neurology, 39(8), 1037–1039.

  9. American Academy of Pediatrics Committee on Drugs. (2001). The transfer of drugs and other chemicals into human milk. Pediatrics, 108(3), 776–789.

  10. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders IV (4th ed.).Washington, DC: American Psychiatric Association.

  11. American Psychiatric Association. (1995). Practice guidelines for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. American Journal of Psychiatry, 152(Suppl II), 1–59. Top of page

  12. American Psychiatric Association. (2000). Diagnostic and statistic manual of mental disorders, text revision (DSM-IV-TR) (Fourth ed.).Washington: APA.

  13. Anderson, P. O. (1977). Drugs and breastfeeding — a review. Drug Intelligence and Clinical Pharmacy, 11, 208–223.

  14. Anggard, E., Jonsson, L. E., Hogmark, A. L. & Gunne, L. M. (1973). Amphetamine metabolism in amphetamine psychosis. Clinical Pharmacology and Therapeutics, 14(5), 870–880.

  15. Angrist, B., Corwin, J., Bartlik, B. & Cooper, T. (1987). Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biological Psychiatry, 22(11), 1357–1368.

  16. Angrist, B. & Gershon, S. (1970). The phenomenology of experimentally induced amphetamine psychosis — preliminary observations. Biological Psychiatry, 2, 95–107.

  17. Angrist, B., Lee, H. K. & Gershon, S. (1974). The antagonism of amphetamine-induced symptomatology by a neuroleptic. American Journal of Psychiatry, 131(7), 817–819.

  18. Angrist, B., Sanfilipo, M. & Wolkin, A. (2001). Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol. Clinical Neuropharmacology, 24(3), 139–144.

  19. Angrist, B., Sathananthan, G., Wilk, S. & Gershon, S. (1974). Amphetamine psychosis: behavioral and biochemical aspects. Journal of Psychiatric Research, 11, 13–23.

  20. Archibald, C. (2002). Drug use in Canada. In Global workshop on drug information systems: activities, methods and future opportunities. Meeting proceedings, December 3–5. Vienna International Centre, Austria: United Nations, New York.

  21. Arcuri, A. (2000). Cessation of amphetamine use in young adults: A qualitative analysis of self-managed change. Unpublished PGDipPsych, Macquarie University.

  22. Auer, J., Berent, R. & Eber, B. (2001). Cardiovascular complications of cocaine use. New England Journal of Medicine, 345(21), 1575–1576.

  23. Auer, J., Berent, R., Weber, T., Lassnig, E. & Eber, B. (2002). Subarachnoid haemorrhage with "Ecstasy" abuse in a young adult. Neurological Sciences, 23(4), 199–201.

  24. Australian Bureau of Criminal Intelligence. (2002). Australian illicit drug report 2001/02. Canberra: Commonwealth of Australia.

  25. Australian Crime Commission. (2003). Australian Illicit Drug Report 2001/02. Canberra: Commonwealth of Australia.

  26. Australian Institute of Health and Welfare. (2002a). 2001 National Drug Strategy Household Survey (AIHW Cat no. PHE 35). Canberra: Australian Institute of Health and Welfare. Top of page

  27. Australian Institute of Health and Welfare. (2002b). 2001 National Drug Strategy Household Survey: First Results (Drug Statistics Series No. 9). Canberra: AIHW.

  28. Australian Institute of Health and Welfare. (2003a). Alcohol and other drug treatment services national minimum data set (AODTS-NMDS): online data cubes. Canberra: Australian Institute of Health and Welfare.

  29. Australian Institute of Health and Welfare. (2003b). National hospital morbidity database: online data cubes. Canberra: Australian Institute of Health and Welfare.

  30. Avants, S. K., Margolin, A., Holford, T. R. & Kosten, T. R. (2000). A randomized controlled trial of auricular acupuncture for cocaine dependence. Archives of Internal Medicine, 160(15), 2305–2312.

  31. Ayd, F. J. J. (1973). Excretion of psychotropic drugs in human breast milk. International Drug Therapy News Bulletin, 8, 33–40.

  32. Azrin, N., Donohue, B., Besalel, V., Kogan, E. & Acierno, R. (1994).Youth drug abuse treatment: a controlled study. Journal of Child and Adolescent Substance Abuse, 3, 1–15.

  33. Back, S. E., Dansky, B. S., Carroll, K. M., Foa, E. B. & Brady, K.T. (2001). Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Description of procedures. Journal of Substance Abuse Treatment, 21(1), 35–45.

  34. Bada, H. S., Das, A., Bauer, C. R., Shankaran, S., Lester, B., Wright, L. L., Verter, J., Smeriglio, V. L., Finnegan, L. P. & Maza, P. L. (2002). Gestational Cocaine Exposure and Intrauterine Growth: Maternal Lifestyle Study. Obstetrics & Gynecology, 100(5), 916–924.

  35. Badon, L. A., Hicks, A., Lord, K., Ogden, B. A., Meleg-Smith, S. & Varner, K. J. (2002). Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. Journal of Pharmacology and Experimental Therapeutics, 302(3), 898–907.

  36. Bailey, G. (1989). Current perspectives on substance abuse in youth. Journal of the American Academy of Child and Adolescent Psychiatry, 28(2), 151–162.

  37. Baker, A., Boggs, T. & Lewin, T. (2001a). Characteristics of regular amphetamine users and implications for treatment. Drug and Alcohol Review, 20, 49–56.

  38. Baker, A., Boggs, T. & Lewin, T. (2001b). Randomized controlled trial of brief cognitive-behavioural interventions among regular users of amphetamine. Addiction, 96, 1279–1287.

  39. Baker, A. & Hambridge, J. (2002). Motivational interviewing: enhancing engagement in treatment for mental health problems. Behaviour Change, 19, 138–145.

  40. Baker, A. & Lee, N. (2003). A review of psychosocial interventions for amphetamine use. Drug and Alcohol Review, 22, 323–335.

  41. Baker, A. & Lee, N. (in press). Chapter 6: Amphetamines. In National Centre for Education and Training on Addiction (Ed.), Alcohol and Other Drugs: A Handbook for Health Professionals. Adelaide: NCETA. Top of page

  42. Balmes, V. P. (2002). ATS: Philippines country profile. Paper presented at the UNODC Regional Inception and Training Meeting for ATS Data and Information Systems, November 3–7 2002, Bangkok.

  43. Bandstra, E. S., Morrow, C. E. & Anthony, J. C. (2001). Longitudinal investigation of task persistence and sustained attention in children with prenatal cocaine exposure. Neurotoxicology and Teratology, 23, 545–559.

  44. Barrett, J., Meehan, O. & Fahy, T. (1996). SSRI and sympathomimetic interaction. British Journal of Psychiatry, 168, 253.

  45. Barrowclough, C., Haddock, G., Tarrier, N., Lewis, S.W., Moring, J., O'Brien, R., Schofield, N. & McGovern, J. (2001). Randomized controlled trial of motivational interviewing, cognitive behaviour therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158, 1706–1713.

  46. Barry, K. L. (1999). Brief interventions and brief therapies for substance use (Treatment Improvement Protocol (TIP) Series No. 34). Rockville, Maryland: US Department of Health and Human Services.

  47. Bashour, T.T. (1994). Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? American Heart Journal, 128(6 Pt 1), 1237–1239.

  48. Bates, A., Clark, M. J., Henderson, R. & Davey, J. (2003). A statewide analysis of QAS attendances at suspected illicit drug incidents in 2001, and non-fatal heroin overdoses from 1997–2001: Report to the Alcohol and Drug Coordination Unit, Queensland Police Service.

  49. Batki, S. L., Moon, J., Delucchi, K. & Bradley, M. (2001). Amlodipine treatment of methamphetamine, a controlled outpatient trial: preliminary analysis.

  50. Batki, S. L., Moon, J., Delucchi, K., Bradley, M., Hersh, D., Smolar, S., Mengis, M., Lefkowitz, E., Sexe, D., Morello, L., Everhart, T., Jones, R.T. & Jacob, P., 3rd. (2000). Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Annals of the New York Academy of Sciences, 909, 260–263.

  51. Batki, S. L., Washburn, A. M., Delucchi, K. & Jones, R.T. (1996). A controlled trial of fluoxetine in crack cocaine dependence. Drug and Alcohol Dependence, 41(2), 137–142.

  52. Battaglia, G., Brooks, B. P., Kulsakdinun, C. & De Souza, E. B. (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. European Journal of Pharmacology, 149(1–2), 159–163.

  53. Battaglia, J., Moss, S., Rush, J., Kang, J., Mendoza, R., Leedom, L., Dubin, W., McGlynn, C. & Goodman, L. (1997). Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine, 15(4), 335–340.

  54. Bauer, C. R., Shankaran, S., Bada, H. S., Lester, B., Wright, L. L., Krause-Steinrauf, H., Smeriglio, V. L., Finnegan, L. P., Maza, P. L. & Verter, J. (2002). The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes. American Journal of Obstetrics and Gynecology, 186(487–195).

  55. Baumann, B. M., Perrone, J., Hornig, S. E., Shofer, F. S. & Hollander, J. E. (2000). Cardiac and hemodynamic assessment of patients with cocaine-associated chest pain syndromes. Journal of Toxicology-Clinical Toxicology, 38(3), 283–290.

  56. Becker, J., Neis, P., Rohrich, J. & Zorntlein, S. (in press). A fatal paramethoxymethamphetamine intoxication. Legal Medicine. Top of page

  57. Becker, J. B. (1999). Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacology Biochemistry and Behavior, 64(4), 803–812.

  58. Beckman, K. J., Parker, R. B., Hariman, R. J., Gallastegui, J. L., Javaid, J. I. & Bauman, J. L. (1991). Hemodynamic and electrophysiological actions of cocaine. Effects of sodium bicarbonate as an antidote in dogs. Circulation, 83(5), 1799–1807.

  59. Behnke, M., Eyler, F. D., Garvan, C.W. & Wobie, K. (2001). The search for congenital malformations in newborns with fetal cocaine exposure. Pediatrics, 107(5), E74.

  60. Behnke, M., Eyler, F. D., Garvan, C.W., Wobie, K. & Hou, W. (2002). Cocaine exposure and developmental outcome from birth to 6 months. Neurotoxicology and Teratology, 24(3), 283–295.

  61. Beitia, G., Cobreros, A., Sainz, L. & Cenarruzabeitia, E. (2000). Ecstasy-induced toxicity in rat liver. Liver, 20(1), 8–15.

  62. Bell, D. S. (1973). The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry, 29, 35–40.

  63. Benchimol, A., Bartall, H. & Desser, K. B. (1978). Accelerated ventricular rhythm and cocaine abuse. Annals of Internal Medicine, 88(4), 519–520.

  64. Bendersky, M. & Lewis, M. (1999). Prenatal cocaine exposure and neonatal condition. Infant Behavior and Development, 22(3), 353–366.

  65. Bennett, D. S., Bendersky, M. & Lewis, M. (2002). Children's Intellectual and Emotional-Behavioral Adjustment at 4 Years as a Function of Cocaine Exposure, Maternal Characteristics, and Environmental Risk. Developmental Psychology, 38(5), 648–658.

  66. Benzaquen, B. S., Cohen, V. & Eisenberg, M. J. (2001). Effects of cocaine on the coronary arteries. American Heart Journal, 142(3), 402–410.

  67. Berlin, C. M., Jr. (1981). Pharmacologic considerations of drug use in the lactating mother. Obstetrics and Gynecology, 58(5 Suppl), 17S–23S.

  68. Berridge, C.W. & Stalnaker, T. A. (2002). Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. Synapse, 46(3), 140–149.

  69. Bertram, S., Barbir, N., Ball, J. & Carroll, T. (2003). National illicit drugs campaign: Evaluation of phase one.

  70. Bick, P. A. & Hannah, A. L. (1986). Intramuscular lorazepam to restrain violent patients. Lancet, 1(8474), 206.

  71. Bieniek, S. A., Ownby, R. L., Penalver, A. & Dominguez, R. A. (1998). A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy, 18(1), 57–62. Top of page

  72. Biller, J., Toffol, G. J., Kassell, N. F., Adams, H. P., Jr., Beck, D.W. & Boarini, D. J. (1987). Spontaneous subarachnoid hemorrhage in young adults. Neurosurgery, 21(5), 664–667.

  73. Bingol, N., Fuchs, M., Diaz, V., Stone, R. K. & Gromisch, D. S. (1987).Teratogenicity of cocaine in humans. Journal of Pediatrics, 110(1), 93–96.

  74. Binson, D., Woods, W. J., Pollack, L. M., Paul, J., Stall, R. & Catania, J. A. (2001). Differential HIV risk in bathhouses and public cruising areas. American Journal of Public Health, 91(9), 1482–1486.

  75. Blaho, K., Merigian, K. & Winbery, S. (1996). Cocaine-associated myocardial ischemia. New England Journal of Medicine, 334(8), 536; author reply 536–537.

  76. Blätter, R., Dobler-Mikola, A., Steffen, T. & Uchtenhagen, A. (2002). Decreasing intravenous cocaine use in opiate users treated with prescribed heroin. Social and Preventative Medicine, 47, 24–32.

  77. Bless, R., Kemmesies, U. & Diemel, S. (2000). 3rd multi-city drug study: drug use trends in 42 European cities in the 1990s. Strasbourg: Council of Europe Publishing.

  78. Bodner, R. A., Lynch, T., Lewis, L. & Kahn, D. (1995). Serotonin syndrome. Neurology, 45(2), 219–223.

  79. Bond, L., Thomas, L., Toumbourou, J., Patton, G. C. & Catalano, R. (2000). Improving the lives of young Victorians in our community: A survey of risk and protective factors (Report prepared for Community Care Division, Department of Human Services). Melbourne, Victoria: Centre for Adolescent Health.

  80. Boniface, K. S. & Feldman, J. A. (2000). Thrombolytic therapy and cocaine-associated acute myocardial infarction. American Journal of Emergency Medicine, 18(5), 612–615.

  81. Boot, B. P., McGregor, I. S. & Hall, W. (2000). MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. The Lancet, 355, 1818–1821.

  82. Botkin, G. J. & Griffin, K.W. (2001). Life skills training: theory, methods and effectiveness of a drug abuse prevention approach. In E. F.Wagner & H. B.Waldron (Eds.), Innovations in adolescent substance abuse interventions. New York: Pergamon.

  83. Botvin, G., Baker, E., Dusenbury, L., Botvin, E. & Diaz, T. (1995). Long-term follow up results of a randomised drug abuse prevention trial in a white middle-class population. Journal of the American Medical Association, April 12, 1106–1112.

  84. Bowdle, T. A. (1998). Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Safety, 19(3), 173–189.

  85. Boys, A., Marsden, J. & Strang, J. (2001). Understanding reasons for drug use amongst young people: a functional perspective. Health Education Research, Theory & Practice, 16(4), 457–469.

  86. Bradbeer, T. M., Fleming, P. M., Charlton, P. & Crichton, J. S. (1998). Survey of amphetamine prescribing in England and Wales. Drug and Alcohol Review, 17, 299–304. Top of page

  87. Brady, K.T., Dansky, B. S., Back, S. E., Foa, E. B. & Carroll, K. M. (2001). Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Preliminary findings. Journal of Substance Abuse Treatment, 21(1), 47–54.

  88. Brauer, L. H., Ambre, J. & De Wit, H. (1996). Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. Journal of Clinical Psychopharmacology, 16(1), 72–76.

  89. Brauer, L. H. & De Wit, H. (1997). High dose pimozide does not block amphetamineinduced euphoria in normal volunteers. Pharmacology Biochemistry and Behavior, 56(2), 265–272.

  90. Brauer, R. B., Heidecke, C. D., Nathrath, W., Beckurts, K.T., Vorwald, P., Zilker, T. R., Schweigart, U., Holscher, A. H. & Siewert, J. R. (1997). Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transplant International, 10(3), 229–233.

  91. Braverman, I., Raviv, E. & Frenkiel, S. (1999). Severe avascular necrosis of the nasal chambers secondary to cocaine abuse. J Otolaryngol, 28(6), 351–353.

  92. Brecht, M. L., von Mayrhauser, C. & Anglin, M. D. (2000). Predictors of relapse after treatment for methamphetamine use. Journal of Psychoactive Drugs, 32(2), 211–220.

  93. Breen, C., Degenhardt, L., Roxburgh, A., Bruno, R., Duquemin, A., Fischer, J., Jenkinson, R., Kinner, S., Longo, M. & Rushforth, C. (2003). Australian Drug Trends 2002: Findings from the Illicit Drug Reporting System (NDARC Monograph No. 50). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  94. Briggs, G. G. (2002). Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol, 45(1), 6–21.

  95. Brody, S. L., Slovis, C. M. & Wrenn, K. D. (1990). Cocaine-related medical problems: consecutive series of 233 patients. American Journal of Medicine, 88(4), 325–331.

  96. Broening, H.W., Morford, L. L., Inman-Wood, S. L., Fukumura, M. & Vorhees, C.V. (2001). 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. Journal of Neuroscience, 21(9), 3228–3235.

  97. Bronson, M. E., Barrios-Zambrano, L., Jiang, W., Clark, C. R., DeRuiter, J. & Newland, M. C. (1994). Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives. Drug and Alcohol Dependence, 36(3), 161–166.

  98. Bronson, M. E., Jiang, W., Clark, C. R. & DeRuiter, J. (1994). Effects of designer drugs on the chicken embryo and 1-day-old chicken. Brain Research Bulletin, 34(2), 143–150.

  99. Brook, R. C. & Whitehead, P. C. (1973). '414': A therapeutic community for the treatment of adolescent amphetamine abusers. Corrective and Social Psychiatry and Journal of Behaviour Therapy, 19(3), 10–19.

  100. Brown, C. & Osterloh, J. (1987). Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). Journal of the American Medical Association, 258(6), 780–781.

  101. Brown, S. A., D'Amic, E. J., McCarthy, D. M. & Tapert, S. F. (2001). Four-year outcomes for adolescent alcohol and drug treatment. Journal of Studies on Alcohol, 62(3), 381–394. Top of page

  102. Brownlow, H. A. & Pappachan, J. (2002). Pathophysiology of cocaine abuse. European Journal of Anaesthesiology, 19(6), 395–414.

  103. Bruno, R. & Mclean, S. (2002). Tasmanian drug trends 2001: findings from the Illicit Drug Reporting System (IDRS) (Technical Report No. 135). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  104. Buckstein, O., Dunne, J., Ayres, W., Arnold, V., Benedek, E., Benson, S., Bernet, W., Bernstein, G., Gross, R., King, R., Kinlan, J., Leonard, H., Licamele, W., McClellan, J. & Shaw, K. (1997). Summary of the practice parameters for the assessment and treatment of children and adolescents with substance use disorder (Supplement). Journal of the American Academy of Child and Adolescent Psychiatry, 36(10), 140–157.

  105. Budavari, S. (1996). The Merck index: an encyclopedia of chemicals, drugs and biologicals (12th ed.). Whitehouse Station, N.J.: Merck & Co.

  106. Buehler, B. A., Conover, B. & Andres, R. L. (1996).Teratogenic potential of cocaine. Seminars in Perinatology, 20(2), 93–98.

  107. Bullock, M. L., Kiresuk, T. J., Pheley, A. M., Culliton, P. D. & Lenz, S. K. (1999). Auricular acupuncture in the treatment of cocaine abuse. Journal of Substance Abuse Treatment, 16(1), 31–38.

  108. Burchell, S. A., Ho, H. C., Yu, M. & Margulies, D. R. (2000). Effects of methamphetamine on trauma patients: a cause of severe metabolic acidosis? Critical Care Medicine, 28(6), 2112–2115.

  109. Bush, H. S. (1988). Cocaine-associated myocardial infarction. A word of caution about thrombolytic therapy. Chest, 94(4), 878.

  110. Buxton, N. & McConachie, N. S. (2000). Amphetamine abuse and intracranial haemorrhage. Journal of the Royal Society of Medicine, 93(9), 472–477.

  111. Byard, R.W., Gilbert, J., James, R. & Lokan, R. J. (1998). Amphetamine derivative fatalities in South Australia—is "Ecstasy" the culprit? American Journal of Forensic Medicine and Pathology, 19(3), 261–265.

  112. Byles, J., Byrne, C., Boyle, M. H. & Offord, D. R. (1988). Ontario child health study: Reliability and validity of the general functioning subscale of the McMaster Family Assessment Device. Family Process, 27, 97–104.

  113. Cairns, P. A. (2001). Drug misuse: conception into childhood. Current Paediatrics, 11, 475–479.

  114. Callaway, C.W. & Clark, R. F. (1994). Hyperthermia in psychostimulant overdose. Annals of Emergency Medicine, 24(1), 68–76.

  115. Campbell, J., Nickel, E. J., Penick, E. C., Wallace, D., Gabrielli, W. F., Rowe, C., Liskow, B., Powell, B. J. & Thomas, H. M. (2003). Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. American Journal on Addictions, 12(2), 122–136.

  116. Campkin, N. J. & Davies, U. M. (1993).Treatment of 'ecstasy' overdose with dantrolene. Anaesthesia, 48(1), 82–83. Top of page

  117. Cantwell, B. & McBride, A. J. (1998). Self detoxification by amphetamine dependent patients: a pilot study. Drug and Alcohol Dependence, 49, 157–163.

  118. Cappon, G. D., Morford, L. L. & Vorhees, C.V. (1998). Enhancement of cocaine-induced hyperthermia fails to elicit neurotoxicity. Neurotoxicology and Teratology, 20, 531–535.

  119. Carbone, J. R. (2000). The neuroleptic malignant and serotonin syndromes. Emergency Medical Clinics of North America, 18(2), 317–325, x.

  120. Carey, K. B. (1997). Challenges in assessing substance use patterns in persons with comorbid mental and addictive disorders. In L. Simon Onken, J. D. Blaine, S. Genser & A. M. Horton (Eds.), NIDA Research Monograph 172:Treatment of Drug-Dependent Individuals with Comorbid Mental Disorders. Rockville, MD: US Department of Health and Human Services.

  121. Carey, K. B. (2002). Clinically useful assessments: substance use and comorbid psychiatric disorders. Behaviour Research and Therapy, 40, 1345–1361.

  122. Carey, K. B. & Correia, C. J. (1998). Severe mental illness and addictions: Assessment considerations. Addictive Behaviors, 23(6), 735–748.

  123. Caribbean Epidemiology Centre (CAREC). (2001). First stakeholders meeting of the Drug Abuse Epidemiological and Surveillance System Project (DAESSP): meeting highlights. Trinidad, 23–35 July 2001.

  124. Carnwath, T., Garvey, T. & Holland, M. (2002). The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence. Journal of Psychopharmacology, 16(4), 373–377.

  125. Carroll, K. M. (1997). Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Addictive Behaviors, 22, 233–245.

  126. Carroll, K. M. (1998). A cognitive-behavioural approach: treating addiction: National Institute on Drug Abuse therapy manuals for drug addiction. US Department of Health and Human Services, National Institute of Health.

  127. Carroll, K. M. (1999). Old psychotherapies for cocaine dependence revisited. Archives of General Psychiatry, 56, 505–506.

  128. Carroll, K. M., Nich, C., Ball, S. A., McCance, E. F. & Rounsaville, B. J. (1998).Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction, 93, 713–728.

  129. Carroll, K. M., Nich, C., Ball, S. A., McCance, E., Frankforter, T. L. & Rounsaville, B. J. (2000). One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addiction, 95(9), 1335–1349.

  130. Carvalho, M., Carvalho, F. & Bastos, M. L. (2001). Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Archives of Toxicology, 74(12), 789–793.

  131. Casriel, C., Des Jarlais, D. C., Rodriguez., R., Friedman, S. R., Stepherson, B. & Khuri, E. (1990).Working with heroin sniffers: Clinical issues in preventing drug injection. Journal of Substance Abuse Treatment, 7, 1–10. Top of page

  132. Catalano, R. F., Hawkins, J. D., Wells, E. A., Miller, J. & Brewer, D. (1990–1991). Evaluation of the effectiveness of adolescent drug abuse treatment, assessment of risks from relapse, and promising approaches for relapse prevention. International Journal of the Addictions, 25, 1085–1140.

  133. Centre for Mental Health, NSW Health Department. (2002). Management of adults with severe behavioural disturbance — guidelines for clinicians in NSW. Gladesville, New South Wales: NSW Health Department.

  134. Cernerud, L., Eriksson, M., Jonsson, B., Steneroth, G. & Zetterstrom, R. (1996). Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatrica, 85(2), 204–208.

  135. Chaiyawong, A. (2002). Drugs situation and the drugs information system in Thailand. In Global workshop on drug information systems: activities, methods and future opportunities, meeting proceedings, December 3–5, 2001, Vienna International Centre, Austria. New York: United Nations.

  136. Chamberlain, G. & Broughton-Pipkin, F. (1998). Clinical physiology in obstetrics (3rd ed.). Oxford: Blackwell Science.

  137. Chambers, R. A. & Druss, B. G. (1999). Droperidol: efficacy and side effects in psychiatric emergencies. Journal of Clinical Psychiatry, 60(10), 664–667.

  138. Chan, B. S., Graudins, A., Whyte, I. M., Dawson, A. H., Braitberg, G. & Duggin, G. G. (1998). Serotonin syndrome resulting from drug interactions. Medical Journal of Australia, 169(10), 523–525.

  139. Chandler, J.V. & Blair, S. N. (1980). The effect of amphetamines on selected physiological components related to athletic success. Medicine and Science in Sports and Exercise, 12(1), 65–69.

  140. Chaplin, S., Sanders, G. L. & Smith, J. M. (1982). Drug excretion into human breast milk. Adverse Drug Reactions and Toxicology Reviews, 1(255–287).

  141. Chapotot, F., Pigeau, R., Canini, F., Bourdon, L. & Buguet, A. (2003). Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Psychopharmacology (Berl), 166(2), 127–138.

  142. Charnaud, B. & Griffiths, V. (1998). Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: a comparison. Drug and Alcohol Dependence, 52, 79–84.

  143. Chase, P. B. & Biros, M. H. (2002). A Retrospective Review of the Use and Safety of Droperidol in a Large, High-risk, Inner-city Emergency Department Patient Population. Academic Emergency Medicine, 9(12), 1402–1410.

  144. Chasnoff, I. J., Chisum, G. M. & Kaplan, W. E. (1988). Maternal cocaine use and genitourinary tract malformations. Teratology, 37(3), 201–204.

  145. Chasnoff, I. J., Griffith, D. R., MacGregor, S., Dirkes, K. & Burns, K. A. (1989).Temporal patterns of cocaine use in pregnancy. Perinatal outcome. Journal of the American Medical Association, 261(12), 1741–1744.

  146. Chasnoff, I. J., Lewis, D. E. & Squires, L. (1987). Cocaine intoxication in a breast-fed infant. Pediatrics, 80(6), 836–838. Top of page

  147. Chaudhuri, C. & Salahudeen, A. K. (1999). Massive intracerebral hemorrhage in an amphetamine addict. American Journal of the Medical Sciences, 317(5), 350–352.

  148. Chen, H. J., Liang, C. L., Lu, K. & Lui, C. C. (2003). Rapidly growing internal carotid artery aneurysm after amphetamine abuse: case report. American Journal of Forensic Medicine and Pathology, 24(1), 32–34.

  149. Chen, K. & Kandel, D. (2002). Relationship between extent of cocaine use and dependence among adolescents and adults in the United States. Drug and Alcohol Dependence, 68, 65–85.

  150. Chermack, S.T. & Blow, F. C. (2002). Violence among individuals in substance abuse treatment: The role of alcohol and cocaine consumption. Drug and Alcohol Dependence, 66(1), 29–37.

  151. Cho, A. K. & Melega, W. P. (2002). Patterns of methamphetamine abuse and their consequences. Journal of Addictive Diseases, 21(1), 21–34.

  152. Churchill, A. C., Burgess, P. M., Pead, J. & Gill, T. (1993). Measurement of the severity of amphetamine dependence. Addiction, 88, 1335–1340.

  153. Chyka, P. A. & Seger, D. (1997). Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Journal of Toxicology-Clinical Toxicology, 35(7), 721–741.

  154. Citrome, L. (2002). Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgraduate Medicine, 112(6), 85–88, 94–96.

  155. Citrome, L. & Volavka, J. (1999). Violent patients in the emergency setting. Psychiatric Clinics of North America, 22(4), 789–801.

  156. Clinton, J. E., Sterner, S., Stelmachers, Z. & Ruiz, E. (1987). Haloperidol for sedation of disruptive emergency patients. Annals of Emergency Medicine, 16(3), 319–322.

  157. Coffey, S. F., Dansky, B. S., Carrigan, M. H. & Brady, K.T. (2000). Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug and Alcohol Dependence, 59(3), 277–286.

  158. Cohen, R. S. (1995). Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Progress in Neuro-psychopharmacology & Biological Psychiatry, 19(7), 1137–1145.

  159. Colado, M. I., O'Shea, E., Granados, R., Misra, A., Murray, T. K. & Green, A. R. (1997). A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. British Journal of Pharmacology, 121(4), 827–833.

  160. Coles, C. D., Bard, K. A., Platzman, K. A. & Lynch, M. E. (1999). Attentional Response at Eight Weeks in Prenatally Drug-Exposed and Preterm Infants. Neurotoxicology and Teratology, 21(5), 527–537.

  161. Comacho, A. & Stein, M. B. (2002). Modafinil for social phobia and amphetamine dependence [letter]. American Journal of Psychiatry, 159(11), 1947–1948. Top of page

  162. Commins, D. L., Vosmer, G., Virus, R., Woolverton, W., Schuster, C. & Seiden, L. (1987). Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. Journal of Pharmacology and Experimental Therapeutics, 241, 338–345.

  163. Commonwealth Department of Health and Aged Care. (1999). Setting the evidence-based research agenda for Australia: literature review. Canberra: National Youth Suicide Prevention Strategy, Commonwealth of Australia.

  164. Commonwealth Department of Health and Aged Care. (2000). Promotion, prevention and early intervention for mental health — a monograph. Canberra: Mental Health and Special Programs Branch, Commonwealth Department of Health and Aged Care.

  165. Community Epidemiological Work Group (CEWG). (2002). Epidemiological trends in drug abuse, advance report, June 2002: US Department of Health and Human Services, National Institute of Health.

  166. Compton, S. N., Burns, B. J., Egger, H. L. & Robertson, E. (2002). Review of the evidence base for treatment of childhood psychopathology: internalising disorders. Journal of Consulting & Clinical Psychology, 70(6), 1240–1266.

  167. Condelli, W., Fairbank, J., Dennis, M. & Rachal, J. (1991). Cocaine use by clients in methadone programs: Significance, scope, and behavioural interventions. Journal of Substance Abuse Treatment, 8, 203–212.

  168. Cone, E. J. (1995). Pharmacokinetics and pharmacodynamics of cocaine. Journal of Analytical Toxicology, 19(6), 459–478.

  169. Connell, P. H. (1958). Amphetamine Psychosis. London: Oxford University Press.

  170. Conway, J. E. & Tamargo, R. J. (2001). Cocaine use is an independent risk factor for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke, 32(10), 2338–2343.

  171. Cook, C. C. H. (1988). The Minnesota model in the management of drug and alcohol dependency: miracle, method or myth? Part 1. The philosophy and the programme. British Journal of Addiction, 83, 625–634.

  172. Cook, C. E., Jeffcoat, A. R., Hill, J. M., Pugh, D. E., Patetta, P. K., Sadler, B. M., White, W. R. & Perez-Reyes, M. (1993). Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metabolism and Disposition, 21(4), 717–723.

  173. Copeland, A. L. & Sorensen, J. L. (2001). Differences between methamphetamine users and cocaine users in treatment. Drug and Alcohol Dependence, 62, 91–95.

  174. Copeland, J., Howard, J., Keogh, T. & Seidler, K. (2003). Patterns and correlates of substance use among juvenile detainees in New South Wales 1998–99. Drug and Alcohol Review, 22(1), 15–21.

  175. Corby, E. A., Roll, J. M., Ledgerwood, D. M. & Schuster, C. R. (2000). Contingency management interventions for treating the substance abuse of adolescents: A feasibility study. Experimental and Clinical Psychopharmacology, 8(3), 371-376.

  176. Cordero, J. F. & Oakley, G. P., Jr. (1983). Drug exposure during pregnancy: some epidemiologic considerations. Clinical Obstetrics and Gynecology, 26(2), 418–428. Top of page

  177. Corse, S. J. (1998). Reducing Substance Abuse During Pregnancy: Discriminating Among Levels of Response in a Prenatal Setting. Journal of Substance Abuse Treatment, 15(5), 457–467.

  178. Costa, G. M., Pizzi, C., Bresciani, B., Tumscitz, C., Gentile, M. & Bugiardini, R. (2001). Acute myocardial infarction caused by amphetamines: a case report and review of the literature. Italian Heart Journal, 2(6), 478–480.

  179. Coulson, G., Went, H. & Kozlinski, E. (1974). Comments on '414': A therapeutic community for the treatment of adolescent amphetamine users. Corrective and Social Psychiatry and Journal of Behaviour Technology, Methods and Therapy, 20(1), 10–12.

  180. Covi, L., Hess, J. M., Kreiter, N. A. & Haertzen, C. A. (1995). Effects of combined fluoxetine and counselling in the outpatient treatment of cocaine abusers. American Journal of Drug and Alcohol Abuse, 21, 327–344.

  181. Crandall, C. G., Vongpatanasin, W. & Victor, R. G. (2002). Mechanism of cocaine-induced hyperthermia in humans. Annals of Internal Medicine, 136(11), 785–791.

  182. Crits-Christoph, P., Siqueland, L., Blaine, J., Frank, A., Lubursky, L., Onken, L. S., Muenz, L. R., Thase, M. E., Weiss, R. D., Gastfriend, D. R., Woody, G. E., Barber, J. P., Butler, S. F., Daley, D., Salloum, I., Bishop, S., Najavits, L. M., Lis, J., Mercer, D., Griffin, M. L., Moras, K. & Beck, A. (1999). Psychosocial treatments for cocaine dependence. Archives of General Psychiatry, 56(6), 493–502.

  183. Croft, R. J., Mackay, A. J., Mills, A.T. & Gruzelier, J. G. (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology Bulletin, 153(3).

  184. Crosby, R. D., Pearson, V. L., Eller, C., Winegarden, T. & Graves, N. L. (1996). Phenytoin in the treatment of cocaine abuse: a double blind study. Clinical Pharmacology & Therapeutics, 59(4), 458.

  185. Cruickshank, C. C. & Dyer, K. R. (unpublished). In-patient symptom triggered management of amphetamine withdrawal: clinical practice and treatment outcome (preliminary results): Western Australia Alcohol and Drug Authority.

  186. Cure, S. & Carpenter, S. (2001). Droperidol for acute psychosis. Cochrane Database Syst Rev, 2, CD002830.

  187. Currier, G.W. & Simpson, G. M. (2001). Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry, 62(3), 153–157.

  188. Dackis, C. A., Lynch, K. G., Yu, E., Samaha, F. F., Kampman, K. M., Cornish, J.W., Rowan, A., Poole, S., White, L. & O'Brien, C. P. (2003). Modafinil and cocaine: a double-blind placebo controlled drug interaction study. Drug and Alcohol Dependence, 70, 29–37.

  189. Dackis, C. A. & O'Brien, C. P. (2002). Cocaine dependence: the challenge for pharmacotherapy. Current Opinion in Psychiatry, 15, 261–267.

  190. Daras, M. (1996). Neurological complications of cocaine. In M. D. Majewkski (Ed.), Neurotoxicity and neuropathology associated with cocaine abuse. Rockville, MD: US Department of Health and Human Services.

  191. Darke, S., Cohen, J., Ross, J., Hando, J. & Hall, W. (1994).Transitions between routes of administration of regular amphetamine users. Addiction, 89, 1077–1083. Top of page

  192. Darke, S. & Hall, W. (1995). Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug and Alcohol Dependence, 39, 231–235.

  193. Darke, S., Hall, W., Heather, N., Wodak, A. & Ward, J. (1992). Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opioid users: the Opiate Treatment Index. British Journal of Addiction, 87, 593–602.

  194. Darke, S., Kaye, S. & Topp, L. (2002a). Cocaine use in New South Wales, Australia, 1996–2000: 5 year monitoring of trends in price, purity, availability and use from the illicit drug reporting system. Drug and Alcohol Dependence, 67(1), 81–88.

  195. Darke, S., Kaye, S. & Topp, L. (2002b). New South Wales drug trends 2001: findings from the Illicit Drug Reporting System (IDRS) (NDARC Technical Report No. 125). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  196. Darke, S., Ross, J. & Cohen, J. (1994). The use of benzodiazepines among regular amphetamine users. Addiction, 89, 1683–1690.

  197. Das Eiden, R. (2001). Maternal substance use and mother-infant feeding interactions. Infant Mental Health Journal, 22(4), 497–511.

  198. Davidson, C., Gow, A. J., Lee, T. H. & Ellinwood, E. H. (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Research Reviews, 36(1), 1–22.

  199. Davis, G. G. & Swalwell, C. I. (1996). The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms. Journal of Forensic Science, 41(4), 626–628.

  200. Dawe, S., Loxton, N. J., Hides, L., Kavanagh, D. J. & Mattick, R. P. (2002). Review of diagnostic screening instruments for alcohol and other drug use and other psychiatric disorders (NDS Monograph Series No. 48, 2nd edition). Canberra: Commonwealth Department of Health and Ageing.

  201. Dawe, S., McKetin, R. & Kingswell, W. (unpublished). The psychiatric comorbidity of stimulant use.

  202. Dawe, S., Saunders, J., Kavanagh, D. & Young, R. (unpublished). An empirical investigation of mental health problems of amphetamine users: A cross sectional study.

  203. Day, C., Topp, L., Rouen, D., Darke, S., Hall, W. & Dolan, K. (2003). Decreased heroin availability in Sydney in early 2001. Addiction, 98(1), 93–95.

  204. de la Torre, R., Farre, M., Ortuno, J., Mas, M., Brenneisen, R., Roset, P. N., Segura, J. & Cami, J. (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. British Journal of Clinical Pharmacology, 49(2), 104–109.

  205. de Lima, M., Soares, B., Reisser, A. & Farrell, M. (2002). Pharmacological treatment of cocaine dependence: a systematic review. Addiction, 97, 931–949.

  206. de Wit, H., Clark, M. & Brauer, L. H. (1997). Effects of d-amphetamine in grouped versus isolated humans. Pharmacology Biochemistry and Behavior, 57(1-2), 333–340. Top of page

  207. de Wit, H., Enggasser, J. L. & Richards, J. B. (2002). Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology, 27(5), 813–825.

  208. Dearlove, J. C., Betteridge, T. J. & Henry, J. A. (1992). Stillbirth due to intravenous amphetamine. British Medical Journal, 304(6826), 548.

  209. Deas, D. & Thomas, S. (2001). An overview of controlled studies of adolescent substance use treatment. The American Journal on Addictions, 10, 178–189.

  210. Deas-Nesmith, D., Brady, K. & Campbell, S. (1998). Comorbid substance use and anxiety disorders in adolescents. Journal of Psychopathology & Behavioural Assessment, 20(2), 139–148.

  211. Degenhardt, L. & Hall, W. (2001). The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychological Medicine, 31, 659–668.

  212. Degenhardt, L., Hall, W. & Lynskey, M. (2001). Alcohol, cannabis and tobacco use among Australians: A comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction, 96, 1603–1614.

  213. Degenhardt, L. & Topp, L. (2003). 'Crystal meth' use among polydrug users in Sydney's dance party subculture: characteristics, use patterns and associated harms. International Journal of Drug Policy, 14(1), 17–24.

  214. Delaney-Black, V., Covington, C., Templin, T., Ager, J., Martier, S. & Sokol, R. (1998). Prenatal cocaine exposure and child behavior. Pediatrics, 102(4 Pt 1), 945–950.

  215. Dennis, D. & Ballard, M. (2002). Ecstasy: It's the rave. The High School Journal, Apr/May, 64–70.

  216. Department of Human Services. (2000). Youth alcohol and drug treatment services — assessment and intervention tool

  217. Derlet, R.W. & Horowitz, B. Z. (1996). Cocaine-associated myocardial ischemia. New England Journal of Medicine, 334(8), 535–536; author reply 536–537.

  218. Derlet, R.W., Rice, P., Horowitz, B. Z. & Lord, R.V. (1989). Amphetamine toxicity: experience with 127 cases. Journal of Emergency Medicine, 7(2), 157–161.

  219. Des Jarlais, D. C., Casriel, C., Friedman, S. R. & Rosenblum, A. (1992). AIDS and the transition to illicit drug injection — results of a randomized trial prevention program. British Journal of Addiction, 87, 493–498.

  220. Dhuna, A., Pascual-Leone, A., Langendorf, F. & Anderson, D. C. (1991). Epileptogenic properties of cocaine in humans. Neurotoxicology, 12 (3), 621–626.

  221. Dielman, T., Butchart, A., Shope, J. & Miller, M. (1990–1991). Environmental correlates of adolescent substance use and misuse: implications for prevention programs. International Journal of Addiction, 25, 855–880. Top of page

  222. Diez-Tejedor, E., Tejada, J. & Frank, A. (1989). Neurologic complications caused by use of cocaine, amphetamines and sympathomimetics. Archivos de Neurobiologia (Madr), 52(Suppl 1), 162–182.

  223. Dillon, P. & Degenhardt, L. (2000). Club drugs. Sydney, New South Wales: National Drug and Alcohol Research Centre.

  224. Dixon, S. D. & Bejar, R. (1989). Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates. Journal of Pediatrics, 115(5 Pt 1), 770–778.

  225. Donovan, S. J. & Nunes, E.V. (1998).Treatment of comorbid affective and substance use disorders: therapeutic potential of anticonvulsants. American Journal on Addictions, 7(3), 210–220.

  226. Dow-Edwards, D. L., Freed-Malen, L. A. & Gerkin, L. M. (2001). Sexual dimorphism in the brain metabolic response to prenatal cocaine exposure. Developmental Brain Research, 129, 73–79.

  227. Dowling, G. P., McDonough, E.T., 3rd & Bost, R. O. (1987). 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. Journal of the American Medical Association, 257(12), 1615–1617.

  228. Downing, J. (1986). The psychological and physiological effects of MDMA on normal volunteers. Journal of Psychoactive Drugs, 18(4), 335–340.

  229. Drake, R. E., Yovetich, N. A., Bebout, R. R., Harris, M. J. & McHugo, G. J. (1997). Integrated treatment for dually diagnosed homeless adults. Journal of Nervous and Mental Disease, 185, 298–305.

  230. Dundee, J.W., Halliday, N. J., Harper, K.W. & Brogden, R. N. (1984). Midazolam. A review of its pharmacological properties and therapeutic use. Drugs, 28(6), 519–543.

  231. Dundee, J.W., Lilburn, J. K., Nair, S. G. & George, K. A. (1977). Studies of drugs given before anaesthesia XXVI: lorazepam. British Journal of Anaesthesia, 49(10), 1047–1056.

  232. Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H. & Whyte, I. M. (in press). Hunter Serotonin Toxicity Criteria: a simple and accurate diagnostic decision rule for serotonin toxicity. Quarterly Journal of Medicine.

  233. Durand, D. J., Espinoza, A. M. & Nickerson, B. G. (1990). Association between prenatal cocaine exposure and sudden infant death syndrome. Journal of Pediatrics, 117(6), 909–911.

  234. Dursun, S. M., Burke, J. G., Nielsen, F. A., Mlynik-Szmid, A. & Reveley, M. A. (1997). SSRI-related toxic serotonin syndrome: improvement upon discontinuation of treatment and propranolol. European Psychiatry, 12(6), 321–323.

  235. Ebrahim, S. H. & Gfroerer, J. (2003). Pregnancy-related substance use in the United States during 1996–1998. Obstetrics & Gynecology, 101(2), 374–379.

  236. Eggert, L. L., Thompson, E. A., Herting, J. R. & Nicholas, L. J. (1994). Prevention research program: Reconnecting at-risk youth. Issues in Mental Health Nursing, 15(107–135). Top of page

  237. Eggert, L. L., Thompson, E. A., Herting, J. R. & Nicholas, L. J. (1995). Reducing suicide potential among high-risk youth: Tests of a school-based prevention program. Suicide and Life Threatening Behavior, 25, 276–296.

  238. Epstein, D. H., Silverman, K., Henningfield, J. E. & Preston, K. L. (1999). Low-dose oral cocaine in humans: acquisition of discrimination and time-course of effects. Behavioural Pharmacology, 10(5), 531–542.

  239. Epstein, E. E. (2001). Classification of alcohol-related problems and dependence. In N. Heather, T. J. Peters & T. Stockwell (Eds.), International handbook of alcohol dependence and problems (pp. 47–70). Chichester: John Wiley & Sons Ltd.

  240. Estroff, T.W., Schwartz, R. H. & Hoffmann, N. G. (1989). Adolescent cocaine abuse. Addictive potential, behavioral and psychiatric effects. Clinical Pediatrics (Phila), 28(12), 550–555.

  241. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2002).Annual report on the state of the drugs problem in the European Union and Norway available on EMCDDA website (www.emcdda.europa.eu). Luxembourg: Office for the Official Publications of the European Communities.

  242. Evans, S. M., Walsh, S. L., Levin, F. R., Foltin, R.W., Fischman, M.W. & Bigelow, G. E. (2001). Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug and Alcohol Dependence, 64, 271–283.

  243. Eyler, F. D., Behnke, M., Garvan, C.W., Woods, N. S., Wobie, K. & Conlon, M. (2001). Newborn evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicology and Teratology, 23(5), 399–411.

  244. Falck, R. S., Wang, J., Carlson, R. G., Eddy, M. & Siegal, H. A. (2002). The prevalence and correlates of depressive symptomatology among a community sample of crack-cocaine smokers. Journal of Psychoactive Drugs, 34(3), 281–288.

  245. Fares, I., McCulloch, K. M. & Raju, T. N. (1997). Intrauterine cocaine exposure and the risk for sudden infant death syndrome: a meta-analysis. Journal of Perinatology, 17(3), 179–182.

  246. Farmer, E. M., Compton, S. N., Burns, B. J. & Robertson, E. (2002). Review of the evidence base for treatment of childhood psychopathology: externalising disorders. Journal of Consulting & Clinical Psychology, 70(6), 1267–1302.

  247. Farrell, A. (1993). Risk factors for drug use in urban adolescents: A three-wave longitudinal study. Journal of Drug Issues, 23(3), 443–462.

  248. Fein, G., Sclafani, V. D. & Meyerhoff, D. J. (2002). Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crack-cocaine dependent men. Drug and Alcohol Dependence, 68, 87–93.

  249. Felgate, H. E., Felgate, P. D., James, R. A., Sims, D. N. & Vozzo, D. C. (1998). Recent paramethoxyamphetamine deaths. Journal of Analytical Toxicology, 22(2), 169–172.

  250. Felix, R. J., Chambers, C. D., Dick, L. M., Johnson, K. A. & Jones, K. L. (2000). Prospective pregnancy outcome in women exposed to amphetamines. Teratology, 61, 441.

  251. Ferris, R. M. & Tang, F. L. (1979). Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of l–[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. Journal of Pharmacology and Experimental Therapeutics, 210(3), 422–428. Top of page

  252. Fessler, R. D., Esshaki, C. M., Stankewitz, R. C., Johnson, R. R. & Diaz, F. G. (1997).The neurovascular complications of cocaine. Surgical Neurology, 47(4), 339–345.

  253. Field, T., Diego, M. & Sanders, C. (2001). Adolescent depression and risk factors. Adolescence, 36(143), 491–498.

  254. Fiorentine, R. (1999). After Drug Treatment: Are 12-Step programs effective in maintaining abstinence? American Journal of Drug and Alcohol Abuse, 25(1), 93–116.

  255. Fiorentine, R. & Hillhouse, M. P. (2000). Drug treatment and 12-step program participation: the additive effects of integrated recovery activities. Journal of Substance Abuse Treatment, 18(1), 65–74.

  256. Fischman, M.W. & Foltin, R.W. (1998). Cocaine self-administration research: Implications for rational therapy. In S.T. Higgins & J. L. Katz (Eds.), Cocaine abuse: Behavior, pharmacology and clinical applications (pp. 181–203). San Diego: Academic Press.

  257. Fisher, A. A. & Davis, M.W. (2002). Serotonin syndrome caused by selective serotonin reuptake-inhibitors — metoclopramide interaction. Annals of Pharmacotherapy, 36(1), 67–71.

  258. Flaum, M. & Schultz, S. K. (1996). When does amphetamine-induced psychosis become schizophrenia? American Journal of Psychiatry, 153(6), 812–815.

  259. Flavin, J. (2002). A glass half full? Harm reduction among pregnant woman who use cocaine. Journal of Drug Issues, 32(2), 973–998.

  260. Flemenbaum, A. (1971). Methylphenidate: a catalyst for the tricyclic antidepressants? American Journal of Psychiatry, 128(2), 239.

  261. Fleming, P. M. & Roberts, D. (1994). Is the prescription of amphetamine justified as a harm reduction measure? Journal of the Royal Society of Health, 114(3), 127–131.

  262. Fletcher, A. M. (2001). Sober for good: New solutions for drinking problems — advice from those who have succeeded. Boston: Houghton Mifflin Company.

  263. Foltin, R.W. & Fischman, M.W. (1988). Ethanol and cocaine interactions in humans: cardiovascular consequences. Pharmacology Biochemistry and Behavior, 31(4), 877–883.

  264. Foltin, R.W., Fischman, M.W., Pedroso, J. J. & Pearlson, G. D. (1987). Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacology Biochemistry and Behavior, 28(4), 459–464.

  265. Fomin, V. P., Singh, D. M., Brown, H. L., Natarajan, V. & Hurd, W.W. (1999). Effect of Cocaine on Intracellular Calcium Regulation in Myometrium From Pregnant Women. Journal of Social Gynecological Investigation, 6(3), 147–152.

  266. Fone, K. C., Beckett, S. R., Topham, I. A., Swettenham, J., Ball, M. & Maddocks, L. (2002). Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl), 159(4), 437–444. Top of page

  267. Forster, P. L., Buckley, R. & Phelps, M. A. (1999). Phenomenology and treatment of psychotic disorders in the psychiatric emergency service. Psychiatric Clinics of North America, 22(4), 735–754.

  268. Fowler, I. L., Carr, V. J., Carter, N.T. & Lewin, T. J. (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin, 24(3), 443–455.

  269. Frank, D. A., Augustyn, M., Knight, W. G., Pell, T. & Zuckerman, B. (2001). Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. Journal of the American Medical Association, 285(12), 1613–1625.

  270. Franklin, T. R., Acton, P., Maldjian, J. A., Gray, J. D., Croft, J. R., Dackis, C. A., O'Brien, C. P. & Childress, A. R. (2002). Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biological Psychiatry, 51, 134–142.

  271. Frederick, D. L., Ali, S. F., Slikker, W., Jr., Gillam, M. P., Allen, R. R. & Paule, M. G. (1995). Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neurotoxicology and Teratology, 17(5), 531–543.

  272. Freese, T. E., Obert, J., Dickow, A., Cohen, J. & Lord, R. H. (2000). Methamphetamine abuse: Issues for special populations. Journal of Psychoactive Drugs, 32, 177–182.

  273. Frei, E., Gamma, A., Pascual-Marqui, R., Lehmann, D., Hell, D. & Vollenweider, F. X. (2001). Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Human Brain Mapping, 14(3), 152–165.

  274. Friedman, A. (1989). Family therapy vs. parent group effects on adolescent drug abusers. American Journal of Family Therapy, 17, 335–347.

  275. Frost, D. O. & Cadet, J. L. (2000). Effects of methamphetamine-induced neurotoxicity on the development of neural circuitry: a hypothesis. Brain Research and Brain Research Reviews, 34(3), 103–118.

  276. Fry, C. & Miller, P. (2002). Victorian Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS) (Technical Report No. 129). Sydney: National Drug and Alcohol Research Centre.

  277. Furr, C. D. M., Delva, J. & Anthony, J. C. (2000). The suspected association between methamphetamine 'ice' smoking and frequent episodes of alcohol intoxication: Data from the 1993 National Household Survey on Drug Abuse. Drug and Alcohol Dependence, 59, 89–93.

  278. Galloway, G. P., Marinelli-Casey, P., Stalcup, J., Lord, R., Christian, D., Cohen, J., Reiber, C. & Vandersloot, D. (2000).Treatment-as-usual in the methamphetamine treatment project. Journal of Psychoactive Drugs, 32, 165–175.

  279. Galloway, G. P., Newmeyer, J., Knapp, T., Stalcup, S. A. & Smith, D. (1996). A controlled trial of imipramine for the treatment of methamphetamine dependence. Journal of Substance Abuse Treatment, 13(6), 493–497.

  280. Gardner, R. & Connell, P. H. (1972). Amphetamine and other non-opioid drug users attending a special drug dependence clinic. British Medical Journal, 2, 322–325.

  281. Gary, N. E. & Saidi, P. (1978). Methamphetamine intoxication. A speedy new treatment. American Journal of Medicine, 64(3), 537–540. Top of page

  282. Garza-Trevino, E. S., Hollister, L. E., Overall, J. E. & Alexander, W. F. (1989). Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry, 146(12), 1598–1601.

  283. Gatley, S. J. (1991). Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochemical Pharmacology, 41(8), 1249–1254.

  284. Gawin, F. H., Khalsa-Denison, M. E. & Jatlow, P. (1996). Flupenthixol-induced aversion to crack cocaine. New England Journal of Medicine, 334(20), 1340–1341.

  285. Geller, B., Cooper, T. & Sun, K. (1998). Double-blind and placebo controlled study of lithium for adolescent bipolar disorders with secondary substance dependence. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 171–178.

  286. George, T. P., Chawarski, M. C., Pakes, J., Carroll, K. M., Kosten, T. R. & Schottenfeld, R. S. (2000). Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry, 47(12), 1080–1086.

  287. Gertner, E. & Hamlar, D. (2002). Necrotizing granulomatous vasculitis associated with cocaine use. J Rheumatol, 29(8), 1795–1797.

  288. Gilbert, E. F. & Khoury, G. H. (1970). Dextroamphetamine and congenital cardiac malformations. Journal of Pediatrics, 76, 638.

  289. Gillman, P. K. (1996). Successful treatment of serotonin syndrome with chlorpromazine. Medical Journal of Australia, 165(6), 345–346.

  290. Gillman, P. K. (1997). Serotonin syndrome treated with chlorpromazine. Journal of Clinical Psychopharmacology, 17(2), 128–129.

  291. Gillman, P. K. (1998). Serotonin syndrome: history and risk. Fundamental & Clinical Pharmacology, 12(5), 482–491.

  292. Gilvarry, E. (2000). Substance abuse in young people. Journal of Child Psychology & Psychiatry & Allied Disciplines, 41(1), 55–80.

  293. Glantz, M. D. & Pickens, R. (1992). Vulnerability to drug abuse. Washington D.C.: American Psychological Association.

  294. Glatt, S. J., Bolanos, C. A., Trksak, G. H. & Jackson, D. (2000). Effects of prenatal cocaine exposure on dopamine system development: a meta-analysis. Neurotoxicology and Teratology, 22(5), 617–629.

  295. Gold, L. H., Hubner, C. B. & Koob, G. F. (1989). A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology, 99(1), 40–47.

  296. Goldberg, R. J. & Huk, M. (1992). Serotonin syndrome from trazodone and buspirone. Psychosomatics, 33, 235–236. Top of page

  297. Goodman, S. J. & Becker, D. P. (1970). Intracranial hemorrhage associated with amphetamine abuse. Journal of the American Medical Association, 212(3), 480.

  298. Goodwin, R. D., Stayner, D. A., Chinman, M. J., Wu, P., Kraemer Tebes, J. & Davidson, L. (2002). The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Comprehensive Psychiatry, 43, 245–252.

  299. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W. & Strang, J. (1995).The severity of dependence scale SDS: Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction, 90, 607–614.

  300. Gossop, M., Griffiths, P., Powis, B. & Strang, J. (1992). Severity of dependence and route of administration of heroin, cocaine and amphetamines. British Journal of Addiction, 87, 1527–1536.

  301. Gossop, M. R., Bradley, B. P. & Brewis, R. K. (1982). Amphetamine withdrawal and sleep disturbance. Drug and Alcohol Dependence, 10(2–3), 177–183.

  302. Gowing, L., Cooke, R., Biven, A. & Watts, D. (2002). Towards better practice in therapeutic communities. Bangalow, New South Wales: Australasian Therapeutic Communities.

  303. Gowing, L., Proudfoot, H., Henry-Edwards, S. & Teesson, M. (2001). Evidence supporting treatment: The effectiveness of interventions for illicit drug use (ANCD Research Paper No. 3). Canberra, ACT: Australian National Council on Drugs.

  304. Gowing, L. R., Henry-Edwards, S. M., Irvine, R. J. & Ali, R. L. (2002). The health effects of ecstasy: a literature review. Drug and Alcohol Review, 21(1), 53–63.

  305. Graber, M. A., Hoehns, T. B. & Perry, P. J. (1994). Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Annals of Pharmacotherapy, 28(6), 732–735.

  306. Grabowski, J., Rhoades, H., Elk, R., Schmitz, J. M. & Creson, D. (1993). Methadone dosage, cocaine and opiate abuse. American Journal of Psychiatry, 150(4), 675.

  307. Grabowski, J., Rhoades, H., Schmitz, J. M., Silverman, P., Stotts, A., Creson, D. & Bailey, R. (2000). Risperidone for the treatment of cocaine dependence: randomised, double-blind trial. Journal of Clinical Psychopharmacology, 21, 522–526.

  308. Grabowski, J., Rhoades, H., Schmitz, J. M., Stotts, A. & Daruzska, L. (2001). Dextroamphetamine for cocaine dependence: randomized, double blind trial. Journal of Clinical Psychopharmacology, 21, 522–526.

  309. Grabowski, J., Roache, J. D., Schmitz, J., Rhoades, H., Creson, D. & Korszun, A. (1998). Replacement medication for cocaine dependence. Journal of Clinical Psychopharmacology, 17, 485–488.

  310. Graham, P. M. (1997). Successful treatment of the toxic serotonin syndrome with chlorpromazine. Medical Journal of Australia, 166(3), 166–167.

  311. Granacher, R. P. & Ruth, D. D. (1979). Droperidol in acute agitation. Current Therapeutic Research-Clinical and Experimental, 25, 361–365. Top of page

  312. Graudins, A., Stearman, A. & Chan, B. (1998).Treatment of the serotonin syndrome with cyproheptadine. Journal of Emergency Medicine, 16(4), 615–619.

  313. Green, A. R., Cross, A. J. & Goodwin, G. M. (1995). Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxmethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology, 119, 247–260.

  314. Greenblatt, D. J., Ehrenberg, B. L., Gunderman, J., Scavone, J. M., Tai, N.T., Harmatz, J. S. & Shader, R. I. (1989). Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. Journal of Pharmacology and Experimental Therapeutics, 250(1), 134–140.

  315. Greer, G. & Tolbert, R. (1986). Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs, 18(4), 319–327.

  316. Gregg, E., Toumbourou, J., Bond, L., Thomas, L. & Patton, G. (2000). Improving the lives of young Victorians in our community: A menu of services. Melbourne: Centre for Adolescent Health.

  317. Gressens, P., Mesples, B., Sahir, N., Marret, S. & Sola, A. (2001). Environmental factors and disturbances of brain development. Seminars in Neonatology, 6(2), 185–194.

  318. Griffith, J. D., Cavanaugh, J. & Oates, J. A. (1969). Schizophreniform psychosis induced by large-dose administration of D-amphetamine. Journal of Psychodelic Drugs, 2, 42–48.

  319. Griffith, J. D., Oates, J. A. & Cavanaugh, J. (1968). Paranoid episodes induced by drug. Journal of the American Medical Association, 205, 39.

  320. Guze, B. H. & Baxter, L. R., Jr. (1986). The serotonin syndrome: case responsive to propranolol. Journal of Clinical Psychopharmacology, 6(2), 119–120.

  321. Halikas, J. A., Crosby, R. D. & Nugent, S. M. (1992). The convergent validity of the Drug Impairment Rating Scale for Cocaine. Psychopharmacology Bulletin, 28, 315–318.

  322. Halikas, J. A., Nugent, S. M., Crosby, R. D. & Carlson, G. A. (1993). 1990–1992 survey of pharmacotherapies used in the treatment of cocaine abuse. Journal of Addictive Diseases, 12(2), 129–139.

  323. Hall, A. P., Lyburn, I. D., Spears, F. D. & Riley, B. (1996). An unusual case of Ecstasy poisoning. Intensive Care Medicine, 22(7), 670–671.

  324. Hall, W. & Carter, L. (2002). Ethical issues in trialing and using a cocaine vaccine to treat and prevent cocaine dependence (NDARC Technical Report No. 140). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  325. Hall, W., Darke, S., Ross, M. & Wodak, A. (1993). Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia. Addiction, 88(4), 509–516.

  326. Hall, W. & Hando, J. (1993). Patterns of illicit psychostimulant use in Australia. In D. Burrows, B. Flaherty & M. MacAvoy (Eds.), Illicit psychostimulant use in Australia. Canberra: Australian Government Publishing Service. Top of page

  327. Hall, W. & Hando, J. (1994). Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug and Alcohol Review, 13(3), 277–284.

  328. Hall, W., Hando, J., Darke, S. & Ross, J. (1996). Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction, 91(1), 81–87.

  329. Hamilton, S. & Malone, K. (2000). Serotonin syndrome during treatment with paroxetine and risperidone. Journal of Clinical Psychopharmacology, 20(1), 103–105.

  330. Hando, J. & Hall, W. (1993). Amphetamine Use Among Young Adults in Sydney, Australia (Research Grant Report No. B93/2; NSW Drug & Alcohol Directorate). Sydney: National Drug and Alcohol Research Centre.

  331. Hando, J., Howard, J. & Zibert, E. (1997). Risky drug practices and treatment needs of youth detained in New South Wales Juvenile Justice Centres. Drug and Alcohol Review, 16(2), 137–145.

  332. Hando, J., O'Brien, S., Darke, S., Maher, L. & Hall, W. (1997). The Illicit Drug Reporting System (IDRS) Trial: Final Report (NDARC Monograph No. 31). Sydney: National Drug and Alcohol Research Centre.

  333. Hando, J., Topp, L. & Hall, W. (1997). Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence, 46, 105–113.

  334. Haney, M., Ward, A. S., Foltin, R.W. & Fischman, M.W. (2001). Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology, 155(4), 330–337.

  335. Hansen, W. (1997). School-based alcohol prevention programs. In K. Bosworth (Ed.), New directions in drug education programs. Bloomington: Phi Delta Kappa International.

  336. Hanson, G. R., Jensen, M., Johnson, M. & White, H. S. (1999). Distinct features of seizures induced by cocaine and amphetamine analogs. European Journal of Pharmacology, 377(2–3), 167–173.

  337. Harrington, H., Heller, H. A., Dawson, D., Caplan, L. & Rumbaugh, C. (1983). Intracerebral hemorrhage and oral amphetamine. Archives of Neurology, 40(8), 503–507.

  338. Hasen, D., Maycock, B. & Lower, T. (2001). 'Weddings, parties, anything...', a qualitative analysis of ecstasy use in Perth, Western Australia. International Journal of Drug Policy, 12(2), 181–199.

  339. Hasin, D., Liu, X., Nunes, E., McCloud, S., Samet, E. & Endicott, J. (2002). Effects of major depression on remission and relapse of substance dependence. Archives of General Psychiatry, 59, 375–376.

  340. Haslett, C. D. & Kumar, S. (2002). Can olanzapine be implicated in causing serotonin syndrome? Psychiatry and Clinical Neurosciences, 56(5), 533–535.

  341. Hawke, J., Jainchill, N. & DeLeon, G. (2000). Adolescent amphetamine users in treatment: Client profiles and treatment outcomes. Journal of Psychoactive Drugs, 32, 95–105. Top of page

  342. Hawkins, J. D., Catalano, R. F., Gillmore, M. R. & Wells, E. A. (1989). Skills training for drug abusers: Generalization, maintenance and effects on drug use. Journal of Consulting and Clinical Psychology, 57, 559–563.

  343. Hawkins, J. D., Catalano, R. F. & Wells, E. A. (1986). Measuring effects of an experimental skills training intervention on drug abusers' skill acquisition. Journal of Consulting and Clinical Psychology, 54, 661–664.

  344. Hawks, D., Mitcheson, M., Ogborne, A. & Edwards, G. (1969). Abuse of methylamphetamine. British Medical Journal, 85, 715–721.

  345. Heard, K., Daly, F. F., O'Malley, G. & Rosen, N. (1999). Respiratory distress after use of droperidol for agitation. Annals of Emergency Medicine, 34(3), 410–411.

  346. Hearn, W. L., Rose, S., Wagner, J., Ciarleglio, A. & Mash, D. C. (1991). Cocaethylene is more potent than cocaine in mediating lethality. Pharmacology Biochemistry and Behavior, 39(2), 531–533.

  347. Heather, N. & Tebbutt, J. (1989). The effectiveness of treatment for drug and alcohol problems: An overview (NCADA Monograph No. 11). Canberra: Australian Government Publishing Service.

  348. Hegerl, U., Bottlender, R., Gallinat, J., Kuss, H. J., Ackenheil, M. & Moller, H. J. (1998). The serotonin syndrome scale: first results on validity. European Archives of Psychiatry & Clinical Neuroscience, 248(2), 96–103.

  349. Heinonen, O. P., Slone, D. & Shapiro, S. (1977). Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group Inc.

  350. Heller, A., Bubula, N., Freeney, A. & Won, L. (2001). Elevation of fetal dopamine following exposure to methamphetamine in utero. Developmental Brain Research, 130, 139–142.

  351. Helmus, T. C., Downey, K. K., Wang, L. M., Rhodes, G. L. & Schuster, C. R. (2001).The relationship between self-reported cocaine withdrawal symptoms and history of depression. Addictive Behaviours, 26(3), 461–467.

  352. Hemeryck, A. & Belpaire, F. M. (2002). Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism, 3(1), 13–37.

  353. Henggeler, S., Bourdin, C., Melton, G., Mann, B., Smith, L., Hall, J., Cone, L. & Fucci, B. (1991). Effects of multisystemic therapy on drug use and abuse in serious juvenile offenders: a progress report from two outcome studies. Family Dynamics and Addiction, 1(40–51).

  354. Henggeler, S.W., Clingempeel, W. G., Brondino, M. J. & Pickrel, S. G. (2002). Four-year follow up of multisystemic therapy with substance-abusing and substance-dependent juvenile offenders. Journal of the American Academy of Child and Adolescent Psychiatry, 41(7), 868–874.

  355. Henningfield, J. E. & Griffiths, R. R. (1981). Cigarette smoking and subjective response: effects of d-amphetamine. Clinical Pharmacology & Therapeutics, 30(4), 497–505.

  356. Henry, J. A. (1992). Ecstasy and the dance of death. British Medical Journal, 305(6844), 5–6. Top of page

  357. Henry, J. A., Jeffreys, K. J. & Dawling, S. (1992).Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet, 340(8816), 384–387.

  358. Herman, J. (1992). Trauma and recovery. London: Pandora.

  359. Hernandez-Lopez, C., Farre, M., Roset, P. N., Menoyo, E., Pizarro, N., Ortuno, J., Torrens, M., Cami, J. & de La Torre, R. (2002). 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 300(1), 236–244.

  360. Herrell, J. M., Taylor, J. A., Gallagher, C. & Dawud-Noursi, S. (2000). Multisite study of the effectiveness of methamphetamine treatment: An initiative of the Centre for Substance Abuse Treatment. Journal of Psychoactive Drugs, 32, 143–147.

  361. Heye, N. & Hankey, G. J. (1996). Amphetamine-associated stroke. Cerebrovascular Disease, 6, 149–155.

  362. Hibell, B., Andersson, B., Ahlström, S., Balakireva, O., Bjarnason, T., Kokkevi, A. & Morgan, M. (2000). The 1997 EPSAD report. Alcohol and other drug use among students in 30 European countries. Stockholm: The Swedish Council for Information on Alcohol and Other Drugs.

  363. Hick, J. L., Mahoney, B. D. & Lappe, M. (2001). Prehospital sedation with intramuscular droperidol: a one-year pilot. Prehospital Emergency Care, 5(4), 391–394.

  364. Hides, L., Dawe, S., Kavanagh, D. & Young, R. (unpublished). A prospective study of the relationship between cannabis use and psychotic symptoms in early psychosis.

  365. Higgins, S.T., Budney, A. J., Bickel, W. K. & Badger, G. J. (1994). Participation of significant others in outpatient behavioral treatment predicts greater cocaine abstinence. American Journal of Drug and Alcohol Abuse, 20(1), 47–56.

  366. Higgins, S.T., Budney, A. J., Bickel, W. K., Foerg, F. E., Donham, R. & Badger, G. J. (1994). Incentives improve outcome in outpatient behavioural treatment of cocaine dependence. Archives of General Psychiatry, 51(7), 568–576.

  367. Higgins, S.T. & Stitzer, M. L. (1989). Monologue speech: effects of d-amphetamine, secobarbital and diazepam. Pharmacology Biochemistry and Behavior, 34(3), 609–618.

  368. Higgins, S.T. & Wong, C. J. (1998).Treating cocaine abuse: What does research tell us? In S.T. Higgins & J. L. Katz (Eds.), Cocaine abuse: Behavior, pharmacology and clinical applications (pp. 343–361). San Diego: Academic Press.

  369. Ho, E., Karimi-Tabesh, L. & Koren, G. (2001). Characteristics of pregnant women who use Ecstasy (3,4-methylenedioxymethamphetamine). Neurotoxicology and Teratology, 23(6), 561–567.

  370. Holden, R. & Jackson, M. A. (1996). Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). Lancet, 347(9007), 1052.

  371. Hollander, J. E. (1995a). Current Concepts: The Management of Cocaine Associated Myocardial Ischemia. New England Journal of Medicine, 333(19), 1267–1272. Top of page

  372. Hollander, J. E. (1995b). The management of cocaine-associated myocardial ischemia. New England Journal of Medicine, 333(19), 1267–1272.

  373. Hollander, J. E., Hoffman, R. S., Burstein, J. L., Shih, R. D. & Thode, H. C., Jr. (1995). Cocaine-associated myocardial infarction. Mortality and complications. Cocaine- Associated Myocardial Infarction Study Group. Archives of Internal Medicine, 155(10), 1081–1086.

  374. Hollander, J. E., Hoffman, R. S., Gennis, P., Fairweather, P., DiSano, M. J., Schumb, D. A., Feldman, J. A., Fish, S. S., Dyer, S. & Wax, P. (1994). Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Academic Emergency Medicine, 1(4), 330–339.

  375. Hong, R., Matsuyama, E. & Nur, K. (1991). Cardiomyopathy associated with the smoking of crystal methamphetamine. Journal of the American Medical Association, 265(9), 1152–1154.

  376. Hooper, J. F. & Minter, G. (1983). Droperidol in the management of psychiatric emergencies. Journal of Clinical Psychopharmacology, 3(4), 262–263.

  377. Horowitz, B. Z. & Mullins, M. E. (1999). Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatric Emergency Care, 15(5), 325–327.

  378. Howard, J. (1994). Irrelevant, unapproachable or boring: treatment issues for drug-using youth. In J. Ross (Ed.), Health for all? Social justice issues in the alcohol and other drug field: proceedings from the Sixth NDARC Annual Symposium. (NDARC Monograph No. 21). Sydney: National Drug and Alcohol Research Centre.

  379. Howard, J. & Arcuri, A. (2003a). PALM stats pack 2002. Sydney, New South Wales: Ted Noffs Foundation.

  380. Howard, J. & Arcuri, A. (2003b). Review of evidence for harm reduction intervention among young drug users to provide prevention of HIV/AIDS. Sydney, New South Wales: Paper prepared for Department of Child and Adolescent Health and Development.Ted Noffs Foundation.

  381. Huber, A., Ling, W., Shoptaw, S., Gulati, V., Brethen, P. & Rawson, R. (1997). Integrating treatments for methamphetamine abuse: A psychosocial perspective. Journal of Addictive Diseases, 16, 41–50.

  382. Huber, A., Lord, R. H., Gulati, V., Marinelli-Casey, P., Rawson, R. & Ling, W. (2000).The CSAT Methamphetamine Treatment Program: Research design accommodations for "real world" application. Journal of Psychoactive Drugs, 32, 149–156.

  383. Hull, P., Rawstorne, P., van de Ven, P., Prestage, G., Kippax, S., Walton, J., Harrison, G., Tunley, F. & Ferguson, G. (2002). Gay community periodic survey, Queensland 2002 (Monograph No. 7/2002). Sydney, New South Wales: National Centre in HIV Social Research, University of New South Wales.

  384. Hull, P., van de Ven, P., Prestage, G., Rawstorne, P., Kippax, S., Horn, G., Kennedy, M., Hussey, G. & Batrouney, C. (2002). Gay community periodic survey, Melbourne 2002 (Monograph No. 5/2002). Sydney, New South Wales: National Centre in HIV Social Research, University of New South Wales.

  385. Hulse, G. & Tait, R. J. (2002). Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug and Alcohol Review, 21, 105–112.

  386. Hung, M. J., Kuo, L.T. & Cherng, W. J. (2003). Amphetamine-related acute myocardial infarction due to coronary artery spasm. International Journal of Clinical Practice, 57(1), 62–64. Top of page

  387. Hunkeler, W., Mohler, H., Pieri, L., Polc, P., Bonetti, E. P., Cumin, R., Schaffner, R. & Haefely, W. (1981). Selective antagonists of benzodiazepines. Nature, 290(5806), 514–516.

  388. Hunt, N., Jones, K. & Shelley, H. (1993).What happens when ecstasy is injected? International Journal of Drug Policy, 4(3), 161–162.

  389. Hunt, N., Stillwell, G., Taylor, C. & Griffiths, P. (1998). Evaluation of a brief intervention to prevent initiation into injecting. Drugs: Education, Prevention and Policy, 5, 185–194.

  390. Hurt, H., Malmud, E., Betancourt, L. M., Brodsky, N. L. & Giannetta, J. M. (2001). A prospective comparison of developmental outcome of children with in utero cocaine exposure and controls using the Battelle Developmental Inventory. Journal of Developmental & Behavioural Pediatrics, 22(1), 27–34.

  391. Iams, J. D. & Rayburn, W. F. (1982). Drug effects on the fetus. In W. F. Rayburn & F. P. Zuspan (Eds.), Drug Therapy in Obstetrics and Gynecology (pp. 9–17). Norwalk, Connecticut: Appleton-Century-Crofts.

  392. IDRS. (2001). Illicit Drug Reporting System Drug Trends Bulletin April 2001. Sydney: National Drug and Alcohol Research Centre.

  393. IDRS. (2002). Intervention and care for psychostimulant users (Illicit Drug Reporting System Drug Trends Bulletin April 2002). Sydney: National Drug and Alcohol Research Centre.

  394. Inaba, T. (1989). Cocaine: pharmacokinetics and biotransformation in man. Canadian Journal of Physiology and Pharmacology, 67(9), 1154–1157.

  395. INCSR. (2002). International narcotics control strategy report on the US Department of State website (www.state.gov) Bureau of International Narcotics and Law Enforcement Affairs, March 2002.

  396. Ireland, K., Southgate, E., Knox, S., van de Ven, P., Howard, J. & Kippax, S. (1999). Using and the 'scene': patterns and contexts of drug use among Sydney gay men (Monograph No. 7). Sydney, New South Wales: National Centre in HIV Social Research, University of New South Wales.

  397. Irvine, R. J., Toop, N. P., Phillis, B. D. & Lewanowitsch, T. (2001). The acute cardiovascular effects of 3,4-methylenedioxymethamphetamine (MDMA) and p-methoxymethamphetamine. Addiction Biology, 6, 45–54.

  398. Israel, J. A. & Lee, K. (2001). Amphetamine usage and genital self-mutilation. Addiction, 97, 1215–1218.

  399. Iwanami, A., Sugiyama, A., Kuroki, N., Toda, S., Kato, N., Nakatani, Y., Horita, N. & Kaneko, T. (1994). Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatrica Scandinavica, 89(6), 428–432.

  400. Jablensky, A., McGrath, J. H., Castele, D., Gureje, O., Evans, M., Carr, V., Morgan, V., Korten, A. & Harvey, C. (2000). Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry, 34, 221–236.

  401. Janowsky, D. S. & Davis, J. M. (1976). Methylphenidate, dextroamphetamine and levanfetamine. Archives of General Psychiatry, 33, 221–236. Top of page

  402. Janowsky, D. S., El-Yousef, M. K., Davis, J. M. & Sekerke, J. H. (1973). Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Archives of General Psychiatry, 28, 185–191.

  403. Janowsky, D. S. & Risch, C. (1979). Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl), 65(1), 73–77.

  404. Jarvis, T. J., Tebbutt, J. & Mattick, R. P. (1995). Treatment approaches for alcohol and drug dependence: An introductory guide. New York: Wiley.

  405. Jenner, L. L., Kavanagh, D. K., Greenaway, L. & Saunders, J. B. (1998). The Dual Diagnosis Consortium Report. Brisbane: ADTRU.

  406. Joanning, H., Quinn, W., Thomas, F. & Mullen, R. (1992).Treating adolescent drug abuse: A comparison of family systems therapy, group therapy and family drug education. Journal of Marital and Family Therapy, 18, 345–356.

  407. Johanson, C. E. & Uhlenhuth, E. H. (1980). Drug preference and mood in humans: d-amphetamine. Psychopharmacology, 71(3), 275–279.

  408. John, D., Kwiatkowski, C. F. & Booth, R. E. (2001). Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry. Drug and Alcohol Dependence, 64, 165–172.

  409. Johnson, B. A., Devous, M. D., Sr., Ruiz, P. & Ait-Daoud, N. (2001).Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. American Journal of Psychiatry, 158(8), 1191–1198.

  410. Johnson, B. A., Roache, J. D., Bordnick, P. S. & Ait-Daoud, N. (1999). Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. Journal of Clinical Psychopharmacology, 144, 295–300.

  411. Johnston, L. D., O'Malley, P. M. & Bachman, J. G. (2002). Monitoring the future national results on adolescent drug use: Overview of the findings, 2001 (NIH Publication No. 02–5105). Bethesda, MD: National Institute on Drug Abuse.

  412. Jones, A. L. & Simpson, K. J. (1999). Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Alimentary Pharmacology and Therapeutics, 13(2), 129–133.

  413. Jones, J. R., Caul, W. F. & Hill, J. O. (1992). The effects of amphetamine on body weight and energy expenditure. Physiology & Behavior, 51(3), 607–611.

  414. Jonsson, L. E., Anggard, E. & Gunne, L. M. (1971). Blockade of intravenous amphetamine euphoria in man. Clinical Pharmacology & Therapeutics, 12(6), 889–896.

  415. Jover, R., Ponsoda, X., Gomez-Lechon, M. J., Herrero, C., del Pino, J. & Castell, J.V. (1991). Potentiation of cocaine hepatotoxicity by ethanol in human hepatocytes. Toxicology and Applied Pharmacology, 107(3), 526–534.

  416. Jufer, R. A., Wstadik, A., Walsh, S. L., Levine, B. S. & Cone, E. J. (2000). Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. Journal of Analytical Toxicology, 24(7), 467–477. Top of page

  417. Kalajian, B. (1992). Family involvement: A more total recovery. Paper presented at the 13th World Conference of Therapeutic Communities: Know Thyself, 23–28 September 1990, Athens.

  418. Kalant, H. (2001). The pharmacology and toxicology of 'ecstasy' (MDMA) and related drugs. Canadian Medical Association Journal, 165(7), 917–928.

  419. Kalechstein, A. D., Newton, T. F., Longshore, D., van Gorp, W. G. & Gawin, F. H. (2000). Psychiatric comorbidity of methamphetamine dependence in a forensic sample. Journal of Neuropsychiatry and Clinical Neurosciences, 12, 480–484.

  420. Kaltenbach, K. (2000). The effects of maternal cocaine abuse on mothers and newborns. Current Psychiatry Reports, 2(6), 514–518.

  421. Kamieniecki, G., Vincent, N., Allsop, S. & Lintzeris, N. (1998). Models of intervention and care for psychostimulant users (Monograph Series No. 32). Canberra, ACT: National Centre for Education and Training on Addiction.

  422. Kaminer, Y. (1994). Adolescent substance abuse: A comprehensive guide to theory and practice. New York: Plenum.

  423. Kaminer, Y. (2000). Contingency management reinforcement procedures for adolescent substance abuse. Journal of the American Academy of Child and Adolescent Psychiatry, 39(10), 1324–1326.

  424. Kaminer, Y. & Burleson, J. A. (1999). Psychotherapies for adolescent substance abuse: 15-month follow up of a pilot study. The American Journal on Addictions, 8, 114–119.

  425. Kaminer, Y., Burleson, J. A., Blitz, C., Sussman, J. & Rousanville, B. J. (1998). Psychotherapies for adolescent substance abusers: a pilot study. The Journal of Nervous and Mental Disease, 186(11), 684–690.

  426. Kaminer, Y., Burleson, J. A. & Goldberger, R. (2002). Cognitive-behavioural coping skills and psychoeducation therapies for adolescent substance abusers. The Journal of Nervous and Mental Disease, 186(11), 684–690.

  427. Kampman, K. M., Pettinati, H., Volpicelli, J. R., Kaempf, G., Turk, E., Insua, A., Lipkin, C., Sparkman, T. & O'Brien, C. P. (2002). Concurrent cocaine withdrawal alters alcohol withdrawal symptoms. Journal of Addictive Diseases, 21(4), 13–26.

  428. Kampman, K. M., Volpicelli, J. R., Alterman, A. I., Cornish, J. & O'Brien, C. P. (2000). Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. American Journal of Psychiatry, 157, 2052–2054.

  429. Kampman, K. M., Volpicelli, J. R., McGinnis, D. E., Alterman, A. I., Weinrieb, R. M., D'Angelo, L. & Epperson, L. E. (1998). Reliability and validity of the Cocaine Selective Severity Assessment. Addictive Behaviours, 23, 449–461.

  430. Kampman, K. M., Volpicelli, J. R., Mulvaney, F. D., Alterman, A. I., Cornish, J., Gariti, P., Cnaan, A., Poole, S., Muller, E., Acosta, T., Luce, D. D. & O'Brien, C. (2001). Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence, 63, 69–78.

  431. Kasirsky, G. (1971).Teratogenic effects of methamphetamine in mice and rabbits. Journal of the American Osteopathic Association, 70(10), 1119–1120. Top of page

  432. Kaskey, G. B. (1992). Possible interaction between an MAOI and "ecstasy". American Journal of Psychiatry, 149, 411–412.

  433. Katz, E., Chutuape, M., Jones, H. & Stitzer, M. (2002).Voucher reinforcement for heroin and cocaine abstinence in an outpatient drug-free program. Experimental and Clinical Psychopharmacology, 10(2), 136–143.

  434. Katz, J. L., Terry, P. & Witkin, J. M. (1992). Comparative behavioral pharmacology and toxicology of cocaine and its ethanol-derived metabolite, cocaine ethyl-ester (cocaethylene). Life Sciences, 50(18), 1351–1361.

  435. Kavanagh, D. J., Mueser, K.T. & Baker, A. Management of comorbidity. In M.Teesson (Ed.), Comorbid mental disorders and substance use disorders: epidemiology, prevention and treatment. Canberra, Australia: Commonwealth Department of Health and Ageing.

  436. Kavanagh, D. J., Young, R., White, A., Saunders, J. B., Wallis, G., Shockley, N., Jenner, L. L. & Clair, A. (in press). A brief intervention for substance abuse in early psychosis. Drug and Alcohol Review.

  437. Kay, S. R., Opler, L. A. & Lindenmayer, J. P. (1988). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Research, 23(1), 99–110.

  438. Kaye, S. & Darke, S. (2000). A comparison of the harms associated with the injection of heroin and amphetamines. Drug and Alcohol Dependence, 58(1–2), 189–195.

  439. Kaye, S., Darke, S. & Topp, L. (2001). An examination of cocaine dependence among injecting and non-injecting cocaine users in Sydney (NDARC Technical Report No. 116). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  440. Keckich, W. A. (1978). Neuroleptics. Violence as a manifestation of akathisia. Journal of the American Medical Association, 240(20), 2185.

  441. Kegeles, L. S., Zea-Ponce, Y., Abi-Dargham, A., Rodenhiser, J., Wang, T., Weiss, R., Van Heertum, R. L., Mann, J. J. & Laruelle, M. (1999). Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse, 31(4), 302–308.

  442. Kelly, J. F., Myers, M. G. & Brown, S. A. (2002). Do adolescents affiliate with 12-step groups? A multivariate process model of effects. Journal of Studies on Alcohol, 63(3), 293–305.

  443. Kelly, J. J., Davis, P. G. & Henschke, P. N. (2000). The drug epidemic: effects on newborn infants and health resource consumption at a tertiary perinatal centre. Journal of Paediatrics & Child Health, 36(3), 262–264.

  444. Kelly, P. A., Ritchie, I. M., Quate, L., McBean, D. E. & Olverman, H. J. (2002). Functional consequences of perinatal exposure to 3, 4-methylenedioxymethamphetamine in rat brains. British Journal of Pharmacology, 137(7), 963–970.

  445. Kema, I. P., de Vries, E. G. & Muskiet, F. A. (2000). Clinical chemistry of serotonin and metabolites. Journal of Chromatography B-Biomedical Applications, 747(1–2), 33–48.

  446. Khellaf, M. & Fenelon, G. (1998). Intracranial hemorrhage associated with cocaine abuse. Neurology, 50(5), 1519–1520. Top of page

  447. King, G. R. & Ellinwood, E. H. (1992). Amphetamine and other stimulants. In J. G. Langrod (Ed.), Substance abuse: A comprehensive textbook. Baltimore, MD: Williams & Wilkins.

  448. Kirby, K. C., Marlowe, D. B., Festinger, D. S., Lamb, R. J. & Platt, J. J. (1998). Schedule of voucher delivery influences initiation of cocaine abstinence. Journal of Consulting & Clinical Psychology, 66(5), 761–767.

  449. Kirsch, H. (Ed.). (1995). Drug lessons and programs in developing countries. New Brunswick: Transaction Publishers.

  450. Kish, S. J. (2002). How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacology, Biochemistry and Behavior, 71(4), 845–855.

  451. Klee, H. (1997). Amphetamine Misuse: International Perspectives on Current Trends. The Netherlands: Harwood Academic Publishers.

  452. Klee, H., Wright, S., Carnwath, T. & Merrill, J. (2001). The role of substitute therapy in the treatment of problem, amphetamine use. Drug and Alcohol Review, 20(4), 417–429.

  453. Klee, H., Wright, S. & Morris, J. (1999). Amphetamine users in treatment: factors associated with sustained abstinence from street drugs. Addiction Research, 7, 239–265.

  454. Klingmann, A., Skopp, G. & Aderjan, R. (2001). Analysis of cocaine, benzoylecgonine, ecogonine methyl ester, and ecgonine by high-pressure liquid chromatography-API mass spectrometry and application to a short-term degradation study of cocaine in plasma. Journal of Analytical Toxicology, 25(6), 425–430.

  455. Klitzman, R. L., Greenberg, J. D., Pollack, L. M. & Dolezal, C. (2002). MDMA ('ecstasy') use, and its association with high risk behaviors, mental health and other factors among gay/bisexual men in New York City. Drug and Alcohol Dependence, 66(2), 115–125.

  456. Knuepfer, M. M. (2003). Cardiovascular disorders associated with cocaine use: myths and truths. Pharmacology and Therapeutics, 97(3), 181–222.

  457. Kolta, M. G., Shreve, P., De Souza, V. & Uretsky, N. J. (1985). Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine. Neuropharmacology, 24, 823–829.

  458. Kosten, T. R., Malison, R. & Wallace, E. (1996). Neuropsychological abnormalities in cocaine abusers: Possible correlates in SPECT neuroimaging. In M. D. Majewkski (Ed.), Neurotoxicity and neuropathology associated with cocaine abuse (Vol. NIDA Monograph 163). Rockville, MD: US Department of Health and Human Services.

  459. Kosten, T. R., Rosen, M., Bond, J., Settles, M., Roberts, J. S. C., Shields, J., Jack, L. & Fox, B. (2002). Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine, 20, 1196–1204.

  460. Kraemer, T. & Maurer, H. H. (2002).Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Therapeutic Drug Monitoring, 24(2), 277–289.

  461. Kratofil, P. H., Baberg, H.T. & Dimsdale, J. E. (1996). Self mutilation and severe self-injurious behaviour associated with amphetamine psychosis. General Hospital Psychiatry, 18(2), 117–120. Top of page

  462. Krenzelok, E. P., McGuigan, M. & Lheur, P. (1997). Position statement: ipecac syrup. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Journal of Toxicology-Clinical Toxicology, 35(7), 699–709.

  463. Krystal, J. H., Price, L. H., Opsahl, C., Ricaurte, G. A. & Heninger, G. R. (1992). Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function. American Journal of Drug and Alcohol Abuse, 18(3), 331–341.

  464. Kuczenski, R., Segal, D. S., Cho, A. K. & Melega, W. (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. Journal of Neuroscience, 15(2), 1308–1317.

  465. Lago, J. A. & Kosten, T. R. (1994). Stimulant withdrawal [review]. Addiction, 89(11), 1477–1481.

  466. Landry, M. J. (1992). An overview of cocaethylene, an alcohol-derived, psychoactive, cocaine metabolite. Journal of Psychoactive Drugs, 24(3), 273–276.

  467. Lange, R. A., Cigarroa, R. G., Flores, E. D., McBride, W., Kim, A. S., Wells, P. J., Bedotto, J. B., Danziger, R. S. & Hillis, L. D. (1990). Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Annals of Internal Medicine, 112(12), 897–903.

  468. Lange, R. A., Cigarroa, R. G., Yancy, C.W., Jr., Willard, J. E., Popma, J. J., Sills, M. N., McBride, W., Kim, A. S. & Hillis, L. D. (1989). Cocaine-induced coronary-artery vasoconstriction. New England Journal of Medicine, 321(23), 1557–1562.

  469. Lange, R. A. & Hillis, L. D. (2001). Medical progress: cardiovascular complications of cocaine use. New England Journal of Medicine, 345(5), 351–358.

  470. Lappin, R. I. & Auchincloss, E. L. (1994).Treatment of the serotonin syndrome with cyproheptadine. New England Journal of Medicine, 331(15), 1021–1022.

  471. Larson, A., Shannon, C. & Eldridge, C. (1999). Indigenous Australians who inject drugs: results from a Brisbane study. Drug and Alcohol Review, 18, 53–62.

  472. Larson, M. (2002). Amphetamine-related psychiatric disorders.

  473. Lason, W. (2001). Neurochemical and pharmacological aspects of cocaine-induced seizures. Polish Journal of Pharmacology, 53(1), 57–60.

  474. Lathers, C. M., Tyau, L. S., Spino, M. M. & Agarwal, I. (1988). Cocaine-induced seizures, arrhythmias and sudden death. Journal of Clinical Pharmacology, 28(7), 584–593.

  475. Lauerma, H. (1998). Interaction of serotonin reuptake inhibitor and 3,4-methylenedioxymethamphetamine? Biological Psychiatry, 43, 923–928.

  476. LeDuc, P. A. & Mittleman, G. (1995). Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology, 121, 407–427. Top of page

  477. Lenox, R. H., Newhouse, P. A., Creelman, W. L. & Whitaker, T. M. (1992). Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Journal of Clinical Psychiatry, 53(2), 47–52.

  478. Lenton, S., Boys, A. & Norcross, K. (1997). Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction, 92(10), 1327–1337.

  479. Leonardi, E.T. & Azmitia, E. C. (1994). MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology, 10(4), 231–238.

  480. Lester, S. J., Baggott, M., Welm, S., Schiller, N. B., Jones, R.T., Foster, E. & Mendelson, J. (2000). Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Annals of Internal Medicine, 133(12), 969–973.

  481. Leviel, V. (2001). The reverse transport of DA, what physiological significance? Neurochemistry International, 38(2), 83–106.

  482. Levin, F. R., Evans, S. M. & Kleber, H. D. (1998). Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug and Alcohol Dependence, 52(1), 15–25.

  483. Levin, F. R., Evans, S. M., McDowell, D. M. & Kleber, H. D. (1998). Methylphenidate treatment for cocaine abusers with attention-deficit/hyperactivity disorder: a pilot study. Journal of Clinical Psychiatry, 59(6), 300.

  484. Lewinsohn, P. M. & Clarke, G. N. (1999). Psychosocial treatments for adolescent depression. Clinical Psychology Review, 19(3), 329–342.

  485. Lewis, R. A., Piercy, F., Sprenkle, D. & Trepper, T. S. (1990). Family-based interventions for helping drug-abusing adolescents. Journal of Adolescent Research, 5, 82–95.

  486. Li, E. C., Feifer, C. & Strohm, M. (2000). A pilot study of control and spiritual beliefs in alcoholics anonymous and smart recovery members. Addictive behaviours, 25(4), 633–640.

  487. Li, S. J., Wang, Y., Pankiewicz, J. & Stein, E. A. (2001). Neurochemical adaptation to cocaine abuse: reduction n-acetyl aspartate in thalamus of human cocaine abusers. Biological Psychiatry, 45, 1481–1487.

  488. Liddle, H., Dakof, G. A., Diamond, G. S., Barrett, K. & Tejeda, M. (2001). Multidimensional family therapy for adolescent drug abuse: results of a randomised clinical trial. American Journal of Drug and Alcohol Abuse, 27, 651–687.

  489. Liddle, H. & Dakof, G. A. (1995). Efficacy of family therapy for drug abuse: promising but not definitive. Journal of Marital and Family Therapy, 21, 511–543.

  490. Lidow, M. S., Bozian, D. & Song, Z. M. (2001). Cocaine affects cerebral neocortical cytoarchitecture in primates only if administered during neocortical neuronogenesis. Developmental Brain Research, 128, 45–52.

  491. Lieb, R., Schuetz, C. G., Pfister, H., von Sydow, K. & Witten, H. (2002). Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug and Alcohol Dependence, 68(2), 195–207. Top of page

  492. Lin, L.Y., Di Stefano, E.W., Schmitz, D. A., Hsu, L., Ellis, S.W., Lennard, M. S., Tucker, G.T. & Cho, A. K. (1997). Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metabolism and Disposition, 25(9), 1059–1064.

  493. Lintzeris, N., Dunlop, A. & Thornton, D. (1999). Getting through amphetamine withdrawal (2nd ed.). Fitzroy, Victoria: Turning Point Alcohol and Drug Centre.

  494. Lintzeris, N., Holgate, F. & Dunlop, A. (1996). Addressing dependent amphetamine use: A place for prescription. Drug and Alcohol Review, 15(2), 189–195.

  495. Lipton, J.W., Ling, Z., Vu, T. Q., Robie, H. C., Mangan, K. P., Weese-Mayer, D. E. & Carvey, P. M. (1999). Prenatal cocaine exposure reduces glial cell line-derived neurotrophic factor (GDNF) in the striatum and the carotid body of the rat: implications for DA neurodevelopment 1. Developmental Brain Research, 118, 231–235.

  496. Lipton, J.W., Vu, T. Q., Ling, Z., Gyawali, S., Mayer, J. R. & Carvey, P. M. (2002). Prenatal cocaine exposure induces an attenuation of uterine blood flow in the rat. Neurotoxicology and Teratology, 24, 143–148.

  497. Little, B. B., Snell, L. M. & Gilstrap, L. C., 3rd. (1988). Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstetrics and Gynecology, 72(4), 541–544.

  498. Little, B. B., Snell, L. M., Klein, V. R. & Gilstrap, L. C., 3rd. (1989). Cocaine abuse during pregnancy: maternal and fetal implications. Obstetrics and Gynecology, 73(2), 157–160.

  499. Little, B. B., Snell, L. M., Trimmer, K. J., Ramin, S. M., Ghali, F., Blakely, C. A. & Garret, A. (1999). Peripartum cocaine use and adverse pregnancy outcome. American Journal of Human Biology, 11(5), 598–602.

  500. Llewellyn-Jones, D., Abraham, S. & Oats, J. (1999). Fundamentals of obstetrics and gynaecology (7th ed.). London: Mosby.

  501. Llosa, T. (1994a). Double-blind trials with oral cocaine as coca tablets (CTA), used for cocaine dependence treatment. In L. S. Harris (Ed.), Problems of drug dependence 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc (NIDA Research Monograph No 153) (Vol. II: Abstracts, pp. 302). Rockville, MD: U.S. Department of Health and Human Services.

  502. Llosa, T. (1994b). The standard low dose of oral cocaine: Used for treatment of cocaine dependence. Substance Abuse, 15(4).

  503. Llosa, T. (1996). Cocalisation:The standard low dose of oral cocaine used as substitution therapy in cocaine dependence (NIDA Research Monograph).

  504. LoCurto, M. J. (1997). The serotonin syndrome. Emergency Medical Clinics of North America, 15(3), 665–675.

  505. Lohrmann, D. K. & Wooley, S. F. (1998). Comprehensive school education. In E. Marx, S. F. Wooley & D. Northrop (Eds.), Health is academic. New York:Teachers College Press.

  506. Lovibond, S. H. & Lovibond, P. H. (1995). Manual for the depression, anxiety and stress scales. Sydney, New South Wales: Psychology Foundation. Top of page

  507. Lukas, S. E., Sholar, M., Kouri, E., Fukuzako, H. & Mendelson, J. H. (1994). Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacology Biochemistry and Behavior, 48(3), 715–721.

  508. Lutiger, B., Graham, K., Einarson, T. R. & Koren, G. (1991). Relationship between gestational cocaine use and pregnancy outcome: A meta-analysis. Teratology, 44, 405–414.

  509. Lyles, J. & Cadet, J. L. (2003). Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Research Reviews, 42, 155–168.

  510. Lynch, K. R., Harrison, J. K. & Pearson, W. R. (1994). Classification of Adrenergic Receptor Subtypes: Molecular Biologic Approaches. Neuroprotocols, 4(1), 14–19.

  511. MacDonald, J., Zhou, J. & Breen, C. (2002). Drug use trends among injecting drug users (IDU). Findings from the Australian Needle and Syringe Program (NSP) Survey, 1995–2001 (Illicit Drug Reporting System Trends Bulletin October 2002). Sydney: National Drug and Alcohol Research Centre.

  512. Macdonald, S. & Wells, S. (2001). Factors related to self-reported violent and accidental injuries. Drug and Alcohol Review, 20(3), 299–307.

  513. Maglione, M., Chao, B. & Anglin, M. D. (2000). Correlates of outpatient drug treatment drop-out among methamphetamine users. Journal of Psychoactive Drugs, 32, 221–228.

  514. Makkai, T. & McGregor, K. (2003). Drug use monitoring in Australia: 2002 annual report on drug use among police detainees (Research and Public Policy Series No. 47). Canberra: Australian Institute of Criminology.

  515. Malbergier, A. & Guerra de Andrade, A. (2001). Depressive disorders and suicide attempts in injecting drug users with and without HIV infection. AIDS Care, 13(1), 141–150.

  516. Malcolm, R., Book, M., Moak, D., DeVane, L. & Czepowicz, V. (2002). Clinical applications of modafinil in stimulant abusers: low abuse potential [letter]. American Journal on Addictions, 11, 247–249.

  517. Malcolm, R., Herron, J., Sutherland, S. E. & Brady, K.T. (2001). Adverse outcomes in a controlled trial of pergolide for cocaine dependence. Journal of Addictive Diseases, 20, 81–92.

  518. Malcolm, R., Moore, J.W., Kajdasz, D. K. & Cochrane, C. E. (1997). Pergolide mesylate. Adverse events occuring in the treatment of cocaine dependence. American Journal on Addictions, 6(2), 117–123.

  519. Mallick, A. & Bodenham, A. R. (1997). MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. Journal of Accident & Emergency Medicine, 14(5), 336–338.

  520. Mao, L., van de Ven, P., Prestage, G., Wang, J., Hua, M., Prihaswan, P. & Ku, A. (2003). Gay community periodic survey, Sydney 2002 (Monograph 1/2003). Sydney, New South Wales: National Centre in HIV Social Research, University of New South Wales.

  521. Margolin, A., Kleber, H. D., Avants, S. K., Konefal, J., Gawin, F., Stark, E., Sorensen, J., Midkiff, E., Wells, E., Jackson, T. R., Bullock, M., Culliton, P. D., Boles, S. & Vaughan, R. (2002). Acupuncture for the treatment of cocaine addiction: A randomised controlled trial. Journal of the American Medical Association, 287(1), 55–63. Top of page

  522. Margolin, A., Kosten, T. R. & Avants, S. K. (1995). A multicentre trial of buproprion for cocaine dependence in methadone-maintained patients. Drug and Alcohol Dependence, 40(2), 125–131.

  523. Mari, A., Arranz, C., Gimeno, X., Lluch, J., Pericot, J., Escuder, O., Monner, A. & Piulachs, P. (2002). Nasal cocaine abuse and centrofacial destructive process: report of three cases including treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 93(4), 435–439.

  524. Marinelli, T. (1996). Rave safe. Sydney: NSW Users and AIDS Association & Northern Sydney Area Health Service.

  525. Mas, M., Farre, M., de la Torre, R., Roset, P. N., Ortuno, J., Segura, J. & Cami, J. (1999). Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4- methylenedioxymethamphetamine in humans. Journal of Pharmacology and Experimental Therapeutics, 290(1), 136–145.

  526. Matera, R. F., Zabala, H. & Jimenez, A. P. (1968). Bifid exencephalia.Teratogen action of amphetamine. International Surgery, 50(1), 79–85.

  527. Matsumoto, T., Kamijo, A., Muiyakawa, T., Endo, K., Yabana, T., Kishimoto, H., Okudaira, K., Sakai, T. & Kosaka, K. (2002). Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction, 97, 809–817.

  528. Mattick, R. P. & Darke, S. (1995). Drug replacement treatments: is amphetamine substitution a horse of a different colour? Drug and Alcohol Review, 14, 389–394.

  529. Mattick, R. P., Kimber, J., Breen, C. & Davoli, M. (2002). Buprenorphine maintenance for opioid dependence (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software.

  530. Maude-Griffin, P. M., Hohenstein, J. M., Humfleet, G. L., Reilly, P. M., Tusel, D. J. & Hall, S. M. (1998). Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: Main and matching effects. Journal of Consulting and Clinical Psychology, 66(5), 832–837.

  531. Maxwell, J. (2003). The response to club drug use. Current Opinion in Psychiatry, 16(279–289).

  532. McBride, A. J., Sullivan, G., Blewett, A. E. & Morgan, S. (1997). Amphetamine prescribing as a harm reduction measure: a preliminary study. Addiction Research, 5, 95–112.

  533. McCance-Katz, E. F., Kosten, T. A. & Kosten, T. R. (2001). Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. Psychopharmacology, 155, 327–329.

  534. McCance-Katz, E. F., Kosten, T. R. & Jatlow, P. (1998). Disulfiram effects on acute cocaine administration. Drug and Alcohol Dependence, 52(1), 27–39.

  535. McDaid, J. & Docherty, J. R. (2001).Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat. British Journal of Pharmacology, 133(3), 429–437.

  536. McDaniel, W.W. (2001). Serotonin syndrome: early management with cyproheptadine. Annals of Pharmacotherapy, 35(7–8), 870–873. Top of page

  537. McElhatton, P. R., Bateman, D. N., Evans, C., Pughe, K. R. & Thomas, S. H. (1999). Congenital anomalies after prenatal ecstasy exposure. Lancet, 354(9188), 1441–1442.

  538. McEvoy, A.W., Kitchen, N. D. & Thomas, D. G. (2000). Lesson of the week: intracerebral haemorrhage in young adults: the emerging importance of drug misuse. British Medical Journal, 320(7245), 1322–1324.

  539. McGuire, T. M., Mitchell, I. B., Wright, A. H. & Noordin, Z. (1987). Update of excretion of drugs and other chemicals into breast milk — part 1. Australian Journal of Hospital Pharmacy, 17, 245–252.

  540. McKetin, R., Darke, S., Bruno, R., Dwyer, R., Kinner, S., Fleming, J., Hargreaves, K., Humeniuk, R. & Rysavy, P. (2000). Australian drug trends 1999. Findings from the Illicit Drug Reporting System (IDRS) (NDARC Monograph No. 43). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  541. McKetin, R. & McKenna, S. (2000). Amphetamine dependence and withdrawal (GP Drug and Alcohol Supplement No. 12): Central Coast Health.

  542. McLellan, A.T., Luborsky, L., Cacciola, J., Griffiths, J., Evans, F., Barr, H. L. & O'Brien, C. P. (1985). New data from the Addiction Severity Index: Reliability and validity in three centres. Journal of Nervous and Mental Disorders, 173, 412–423.

  543. Mediavilla, A., Feria, M., Fernandez, J. F., Cagigas, P., Pazos, A. & Florez, J. (1979).The stimulatory action of d-amphetamine on the respiratory centre, and its mediation by a central alpha-adrenergic mechanism. Neuropharmacology, 18(2), 133–142.

  544. Melin, G. L. & Gotestam, K. G. (1973). A contingency management program on a drug-free unit for intravenous amphetamine addicts. Journal of Behaviour Therapy and Experimental Psychiatry, 4, 331–337.

  545. Mendelson, J., Jones, R.T., Upton, R. & Jacob, P., 3rd. (1995). Methamphetamine and ethanol interactions in humans. Clinical Pharmacology & Therapeutics, 57(5), 559–568.

  546. Mendelson, J. H., Mello, N. K., Sholar, M. B., Siegel, A. J., Mutschler, N. & Halpern, J. (2002).Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology, 27(1–2), 71–82.

  547. Merigian, K. S. & Roberts, J. R. (1987). Cocaine intoxication: hyperpyrexia, rhabdomyolysis and acute renal failure. Journal of Toxicology-Clinical Toxicology, 25(1–2), 135–148.

  548. Merkel, P. A., Koroshetz, W. J., Irizarry, M. C. & Cudkowicz, M. E. (1995). Cocaine-associated cerebral vasculitis. Seminars in Arthritis and Rheumatism, 25(3), 172–183.

  549. Meyer, J. S. & Ali, S. F. (2002). Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain. Annals of New York Academy of Science, 965, 373–380.

  550. Michelotti, G. A., Price, D.T. & Schwinn, D. A. (2000). Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacology and Therapeutics, 88(3), 281–309.

  551. Miczek, K. A. & Tidey, J.W. (1989). Amphetamines: aggressive and social behavior. In K. Asghar & E. De Souza (Eds.), Pharmacology and Toxicology of Amphetamine and Related Designer Drugs (NIDA Research Monograph No 94) (pp. 68–100). Rockville, MD: US Department of Health and Human Services. Top of page

  552. Midford, R., Munro, G., McBride, N., Snow, P. & Ladzinsji, U. (2002). Principles that underpin effective school based education. Journal of Drug Education, 32(4), 363–386.

  553. Milby, J. B., Schumacher, J. E., McNamara, C., Wallace, D., Usdan, S., McGill, T. & Michael, M. (2000). Initiating abstinence in cocaine abusing dually diagnosed homeless persons. Drug and Alcohol Dependence, 60, 55–67.

  554. Milkovich, L. & van der Berg, B. J. (1977). Effects of antenatal exposure to anorectic drugs. American Journal of Obstetrics and Gynecology, 129(6), 637–642.

  555. Miller, D. B. & O'Callaghan, J. P. (2003). Elevated environmental temperature and methamphetamine neurotoxicity. Environmental Research, 92, 48–53.

  556. Miller, N. S., Summers, G. L. & Gold, M. S. (1993). Cocaine dependence: Alcohol and other drug dependence and withdrawal characteristics. Journal of Addictive Diseases, 12(1), 25–35.

  557. Miller, P. R., Dasher, R., Collins, R., Griffiths, P. & Brown, F. (2001). Inpatient diagnostic assessments: 1. Accuracy of structured vs. unstructured interviews. Psychiatry Research, 105(3), 255–264.

  558. Mills, K. C. (1997). Serotonin syndrome. A clinical update. Critical Care Clinics, 13(4), 763–783.

  559. Milroy, C. M., Clark, J. C. & Forrest, A. R. (1996). Pathology of deaths associated with "ecstasy" and "eve" misuse. Journal of Clinical Pathology, 49(2), 149–153.

  560. Ministry of Health, Labour and Welfare. (2002). The general situation of administrative measures against narcotics and stimulants of abuse. Japan: Ministry of Health, Labour and Welfare.

  561. Minkoff, K. (1989). An integrated treatment model for dual diagnosis of psychosis and addiction. Hospital and Community Psychiatry, 40, 1031–1036.

  562. Mitchell, P., Spooner, C., Copeland, J., Vimpani, G., Toumbourou, J., Howard, J. & Sanson, A. (2001). The role of families in the development, identification, prevention and treatment of illicit drug problems. Canberra, Australia: National Health and Medical Research Council.

  563. Moliterno, D. J., Willard, J. E., Lange, R. A., Negus, B. H., Boehrer, J. D., Glamann, D. B., Landau, C., Rossen, J. D., Winniford, M. D. & Hillis, L. D. (1994). Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. New England Journal of Medicine, 330(7), 454–459.

  564. Moncher, M. S., Holden, G.W. & Schinke, S. P. (1991). Psychosocial correlates of adolescent substance use: A review of current aetiological constructs. International Journal of the Addictions, 26, 377–414.

  565. Monti, P. M., Rohsenow, D. J., Michalec, E., Martin, R. A. & Abrams, D. B. (1997). Brief coping skills treatment for cocaine abuse: Substance use outcomes at three months. Addiction, 92(12), 1717–1728.

  566. Moolchan, E.T., Cone, E. J., Wstadik, A., Huestis, M. A. & Preston, K. L. (2000). Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. Journal of Analytical Toxicology, 24(7), 458–466. Top of page

  567. Moore, D. & Saunders, B. (1991).Youth drug use and the prevention of problems. International Journal on Drug Policy, 2(5), 13–15.

  568. Moriya, F. & Hashimoto, Y. (2002). A case of fatal hemorrhage in the cerebral ventricles following intravenous use of methamphetamine. Forensic Science International, 129(2), 104–109.

  569. Morrow, B. A., Elsworth, J. D. & Roth, R. H. (2002). Prenatal cocaine exposure disrupts non-spatial, short-term memory in adolescent and adult male rats. Behavioural Brain Research, 129, 217–223.

  570. Morrow, C. E., Bandstra, E. S., Anthony, J. C., Ofir, A.Y., Xue, L. & Reyes, M. L. (2001). Influence of prenatal cocaine exposure on full-term infant neurobehavioral functioning. Neurotoxicology and Teratology, 23, 533–544.

  571. Muck, R., Zempolich, K. A., Titus, J. C., Fishman, K., Godley, M. D. & Schwebel, R. (2001). An overview of the effectiveness of adolescent substance abuse treatment models. Youth and Society, 33(2), 143–168.

  572. Mueller, P. D. & Korey, W. S. (1998). Death by "ecstasy": the serotonin syndrome? Annals of Emergency Medicine, 32(3 Pt 1), 377–380.

  573. Murray, P., Lintzeris, N., Gijsbers, A. & Dunlop, A. (2002). Clinical Treatment Guidelines for Alcohol and Drug Clinicians. Number 9: Prescribing for drug withdrawal. Fitzroy, Melbourne: Turning Point Alcohol and Drug Centre.

  574. Musshoff, F. (2000). Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metabolism Reviews, 32(1), 15–44.

  575. Myles, J. (1997).Treatment for amphetamine misuse in the United Kingdom. In H. Klee (Ed.), Amphetamine misuse: International perspectives on current trends (pp. 69–79).The Netherlands: Harwood Academic Publishers.

  576. Naeye, R. L. (1983). Maternal use of dextroamphetamine and growth of the fetus. Pharmacology, 26(2), 117–120.

  577. Nakatani, Y. & Hara, T. (1998). Disturbance of consciousness due to methamphetamine abuse. A study of 2 patients. Psychopathology, 31(3), 131–137.

  578. Nanda, A., Vannemreddy, P. S., Polin, R. S. & Willis, B. K. (2000). Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators. Neurosurgery, 46(5), 1063–1067; discussion 1067–1069.

  579. Nanji, A. A. & Filipenko, J. D. (1984). Asystole and ventricular fibrillation associated with cocaine intoxication. Chest, 85(1), 132–133.

  580. Nann-Vernotica, E., Donny, E. C., Bigelow, G. E. & Walsh, S. L. (2001). Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacologia, 155(4), 338–347.

  581. Natera Rey, G. (2002). Mexico. In Global workshop on drug information systems: activities, methods and future opportunities. Meeting proceedings, December 3–5, 2001, Vienna International Centre, Austria. New York: United Nations. Top of page

  582. National Campaign Against Drug Abuse (NCADA). (1992). Comparative analysis of illicit drug strategy (Monograph Series No. 18). Canberra: Australian Government Publishing Service.

  583. National Centre for HIV Epidemiology and Clinical Research. (2002). HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Sydney: National Centre for HIV Epidemiology and Clinical Research, University of NSW.

  584. National Crime Prevention. (1999a). Living rough: Preventing crime and victimisation among homeless young people. Canberra: Attorney-General's Department.

  585. National Crime Prevention. (1999b). Pathways to prevention: Developmental and early intervention approaches to crime in Australia. Report findings. Canberra: Attorney General's Department.

  586. National Drug and Alcohol Research Centre. (2003). Guidelines for the treatment of alcohol problems. Canberra, Australia: Commonwealth of Australia.

  587. National Health and Medical Research Council. (1999). A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra, Australia: Commonwealth of Australia.

  588. National Institute on Drug Abuse. (1997). Preventing drug use among children and adolescents — A research based guide, from the NIDA website (www.drugabuse.gov).

  589. National Institute on Drug Abuse. (2002). Drug abuse prevention research update. NIDA Notes, 16(6), February from the NIDA website (www.drugabuse.gov).

  590. National Perinatal Statistics Unit. (2001). Congenital Malformations, Australia, 1981–1997: Australian Institute of Health and Welfare (AIHW).

  591. Neave, G. (1994). Midazolam for acute agitation in the psychiatric patient. Australian Journal of Hospital Pharmacy, 24, 356.

  592. Newcomb, M. & Felix-Ortiz, M. (1992). Multiple protective and risk factors for drug use and abuse: cross-sectional and prospective findings. Journal of Personal and Social Psychology, 63, 280–296.

  593. Nolte, K. B., Brass, L. M. & Fletterick, C. F. (1996). Intracranial hemorrhage associated with cocaine abuse: a prospective autopsy study. Neurology, 46(5), 1291–1296.

  594. Nora, J. J. (1968). Maternal exposure to potential teratogens. Journal of the American Medical Association, 203(12), 1075–1076.

  595. Nora, J. J., McNamara, D. G. & Fraser, F. C. (1967). Dextroamphetamine sulphate and human malformations. The Lancet, 1, 570–571.

  596. Nora, J. J., Trasler, D. G. & Fraser, F. C. (1965). Malformations in mice induced by dexamphetamine sulphate. Lancet, 2(7420), 1021–1022. Top of page

  597. Nora, J. J., Vargo, T. A., Nora, A. H., Love, K. E. & McNamara, D. G. (1970). Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet, 1(7659), 1290–1291.

  598. Nordt, S. P. & Clark, R. F. (1997). Midazolam: a review of therapeutic uses and toxicity. Journal of Emergency Medicine, 15(3), 357–365.

  599. Nunes, E.V., McGrath, P. J., Quitkin, F. M., Opeceek-Welkikson, K., Stewart, J.W., Koenig, T., Wager, S. & Klein, D. F. (1995). Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug and Alcohol Dependence, 39(3), 185–195.

  600. Obert, J. L., McCann, M. J., Marinelli-Casey, P., Weiner, A., Minsky, S., Brethen, P. & Rawson, R. (2000).The Matrix Model of outpatient stimulant abuse treatment: History and description. Journal of Psychoactive Drugs, 32, 157–164.

  601. O'Brien, T. E. (1974). Excretion of drugs in human milk. American Journal of Hospital Pharmacy, 31(9), 844–854.

  602. O'Cain, P. A., Hletko, S. B., Ogden, B. A. & Varner, K. J. (2000). Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiology & Behavior, 70(1–2), 141–148.

  603. O'Connor, K. P. & Bradley, B. (1990). Cognitive cues for use in a case of amphetamine sulfate abuse. The Journal of Nervous and Mental Disease, 178, 271–272.

  604. Ohnaka, H., Ukita, K., Yamamasu, S., Inoue, M., Imanaka, M., Ishiko, O. & Ogita, S. (2001). Effects of cocaine and ethanol on mouse fetuses. Osaka City Medical Journal, 47(1), 83–93.

  605. Oliveto, A., Kosten, T. R., Schottenfeld, R., Falcioni, J. & Ziedonis, D. (1995). Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. Journal of Substance Abuse Treatment, 12(6), 423–428.

  606. Oliveto, A., McCance-Katz, E. F., Singha, A., Petrakis, I., Hameedi, F. & Kosten, T. R. (2001). Effects of cocaine prior to and during buproprion maintenance in cocaine-abusing volunteers. Drug and Alcohol Dependence, 63, 155–167.

  607. Ornstein, T. J., Iddon, J. L., Baldacchino, A. M., Sahakian, B. J., London, M., Everitt, B. J. & Robbins, T.W. (2000). Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology, 23(2), 113–126.

  608. Oro, A. S. & Dixon, S. D. (1987). Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. Journal of Pediatrics, 111(4), 571–578.

  609. Overall, J. E. & Gorham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports, 10, 799–812.

  610. Ozechowski, T. J. & Liddle, H. A. (2000). Family-based therapy for adolescent drug abuse: knowns and unknowns. Clinical and Family Psychology Review, 3, 269–298.

  611. Paine, T. A., Jackman, S. L. & Olmstead, M. C. (2002). Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydramine. Behavioural Pharmacology, 13(7), 511–523. Top of page

  612. Palmgreen, P., Donohew, L., Lorch, E. P., Hoyle, R. & Stephenson, M.T. (2001).Television campaigns and adolescent marijuana use:Tests of sensation seeking targeting. American Journal of Public Health, 91(2), 292–296.

  613. Papalia, D. (1989). Lifespan development. Sydney: McGraw Hill.

  614. Parr, M. J., Low, H. M. & Botterill, P. (1997). Hyponatraemia and death after "ecstasy" ingestion. Medical Journal of Australia, 166(3), 136–137.

  615. Parrott, A. C. (2002). Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacology, Biochemistry and Behavior, 71(4), 837–844.

  616. Parrott, A. C., Buchanan, T., Scholey, A. B., Heffernan, T., Ling, J. & Rodgers, J. (2002). Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Human Psychopharmacology, 17(6), 309–312.

  617. Patel, T. G., Laungani, R. G., Grose, E. A. & Dow-Edwards, D. L. (1999). Cocaine Decreases Uteroplacental Blood Flow in the Rat. Neurotoxicology and Teratology, 21(5), 559–565.

  618. Pates, R., Coombes, N. & Ford, N. (1996). A pilot programme in prescribing dexamphetamine for amphetamine users (part 1). Journal of Substance Misuse for Nursing, Health & Social Care, 1(2), 80–84.

  619. Patterson, K. M., Holman, C. D. J., English, D. R., Hulse, G. K. & Unwin, W. (1999). First-time hospital admissions with illicit drug problems in Indigenous and non-Indigenous Western Australians: an application of record linkage to public health surveillance. Australia and New Zealand Journal of Public Health, 23(5), 460–463.

  620. Pead, J., Lintzeris, N. & Churchill, A. (1996). Amphetamines and analogues: The trainer's package for health professionals. Canberra: Commonwealth of Australia.

  621. Pennings, E. J., Leccese, A. P. & Wolff, F. A. (2002). Effects of concurrent use of alcohol and cocaine. Addiction, 97(7), 773–783.

  622. Perez, J. A., Jr., Arsura, E. L. & Strategos, S. (1999). Methamphetamine-related stroke: four cases. Journal of Emergency Medicine, 17(3), 469–471.

  623. Peroutka, S. J., Newman, H. & Harris, H. (1988). Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology, 1(4), 273–277.

  624. Petitti, D. B., Sidney, S., Queensbury, C. & Bernstein, A. (1998). Stroke and cocaine or amphetamine use. Epidemiology, 9(6), 596–600.

  625. Petrakis, I. L., Carroll, K. M., Nich, C., Gordon, L., Kosten, T. & Rounsaville, B. (1998). Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug and Alcohol Dependence, 50(3), 221–226.

  626. Petrakis, I. L., Carroll, K. M., Nich, C., Gordon, L.T., McCance-Katz, E. F., Frankforter, T. & Rounsaville, B. J. (2000). Disulfiram treatment for cocaine dependence in methadonemaintained opioid addicts. Addiction (219–228). Top of page

  627. Pigeau, R., Naitoh, P., Buguet, A., McCann, C., Baranski, J., Taylor, M., Thompson, M. & Mac, K. I. I. (1995). Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res, 4(4), 212–228.

  628. Platt, J. J. (1997). Cocaine addiction: theory, research and treatment. Cambridge, Massachusetts: Harvard University Press.

  629. Poshyachinda, V., Perngparn, U. & Ngowabunpat, A. (2002). Status of drug and substance use: 2001 National Household Survey, preliminary report.

  630. Powell, J. E. & Taylor, D. (1989). Evaluation of a residential detoxification and motivational program: the Wollongong Crisis Centre (Report of a project funded by the Australian research into drug abuse program of the National Campaign Against Drug Abuse). Canberra: Commonwealth of Australia.

  631. Prior, F. H., Isbister, G. K., Dawson, A. H. & Whyte, I. M. (2002). Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine. Medical Journal of Australia, 176(5), 240–241.

  632. Prochaska, J. O., DiClemente, C. C. & Norcross, J. C. (1992). In search of how people change. American Psychologist, 47, 1102–1114.

  633. Proudfoot, H. & Teesson, M. (2000). Investing in drug and alcohol treatment (NDARC Technical Report No. 91). Sydney: National Drug and Alcohol Research Centre.

  634. Qureshi, A. I., Suri, M. F., Guterman, L. R. & Hopkins, L. N. (2001). Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation, 103(4), 502–506.

  635. Racine, A., Joyce, T. & Anderson, R. (1993). The association between prenatal care and birth weight among women exposed to cocaine in New York City. Journal of the American Medical Association, 270(13), 1581–1586.

  636. Radomski, J.W., Dursun, S. M., Reveley, M. A. & Kutcher, S. P. (2000). An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Medical Hypotheses, 55(3), 218–224.

  637. Rajput, V. & Sunnergren, K. P. (1996). Cocaine-associated myocardial ischemia. New England Journal of Medicine, 334(8), 536; author reply 536–537.

  638. Ramamoorthy, J. D., Ramamoorthy, S., Leibach, F. H. & Ganapathy, V. (1995). Human placental monoamine transporters as targets for amphetamines. American Journal of Obstetrics and Gynecology, 173(6), 1782–1787.

  639. Ramamoorthy, Y., Yu, A. M., Suh, N., Haining, R. L., Tyndale, R. F. & Sellers, E. M. (2002). Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochemical Pharmacology, 63(12), 2111–2119.

  640. Ramer, C. M. (1974). The case history of an infant born to an amphetamine-addicted mother. Clinical Pediatrics, 13, 596–597.

  641. Randall, C. L., Cook, J. L., Thomas, S. E. & White, N. M. (1999). Alcohol Plus Cocaine Prenatally Is More Deleterious Than Either Drug Alone. Neurotoxicology and Teratology, 21(6), 673–678. Top of page

  642. Randall, T. (1992). Cocaine, alcohol mix in body to form even longer lasting, more lethal drug. Journal of the American Medical Association, 267(8), 1043–1044.

  643. Rasmussen, S. G., Carroll, F. I., Maresch, M. J., Jensen, A. D., Tate, C. G. & Gether, U. (2001). Biophysical characterization of the cocaine binding pocket in the serotonin transporter using a fluorescent cocaine analogue as a molecular reporter. Journal of Biological Chemistry, 276(7), 4717–4723.

  644. Rawson, R., Gonzales, R. & Brethen, P. (2002).Treatment of methamphetamine use disorders: an update. Journal of Substance Abuse Treatment, 23(145–150).

  645. Rawson, R. A. (1999). Treatment for stimulant use disorders (Treatment Improvement Protocol (TIP) Series No. 33). Rockville, Maryland: US Department of Health and Human Services.

  646. Rawson, R. A., Anglin, M. D. & Ling, W. (2002). Will the methamphetamine problem go away? Journal of Addictive Diseases, 21(1), 5–19.

  647. Rawson, R. A., Huber, A., Brethen, P., Obert, J., Gulati, V., Shoptaw, S. & Ling, W. (2000). Methamphetamine and cocaine users: Differences in characteristics and treatment retention. Journal of Psychoactive Drugs, 32, 233–238.

  648. Rawson, R. A., Huber, A., Brethen, P., Obert, J., Gulati, V., Shoptaw, S. & Ling, W. (2002). Status of methamphetamine users 2–5 years after outpatient treatment. Journal of Addictive Diseases, 21, 107–119.

  649. Rawson, R. A., McCann, M. J., Huber, A., Marinelli-Casey, P. & Williams, L. (2000). Moving research into community settings in the CSAT methamphetamine treatment project: the coordinating centre perspective. Journal of Psychoactive Drugs, 32, 201–208.

  650. Refuerzo, J. S., Sokol, R. J., Blackwell, S. C., Berry, S. M., Janisse, J. J. & Sorokin, Y. (2002). Cocaine use and preterm premature rupture of membranes: Improvement in neonatal outcome. American Journal of Obstetrics and Gynecology, 186, 1150–1154.

  651. Regier, D., Farmer, M. E., Rae, D. S. & Myers, J. K. (1993). One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment Area program. Acta Psychiatrica Scandinavica, 88(1), 35–47.

  652. Reiber, C., Galloway, G., Cohen, J., Hsu, J. C. & Lord, R. H. (2000). A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months. Journal of Psychoactive Drugs, 32, 183–191.

  653. Resnick, M. & Burton, B.T. (1984). Droperidol vs. haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry, 45(7), 298–299.

  654. Ressler, K. J. & Nemeroff, C. B. (1999). Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biological Psychiatry, 46(9), 1219–1233.

  655. Ricaurte, G. A., DeLanney, L. E., Irwin, I. & Langston, J.W. (1988).Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Research, 446, 165–168.

  656. Ricaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J. & McCann, U. D. (2002). Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science, 297(5590), 2260–2263. Top of page

  657. Richards, J. R. & Brofeldt, B.T. (2000). Patterns of tooth wear associated with methamphetamine use. Journal of Periodontology, 71(8), 1371–1374.

  658. Richards, J. R., Derlet, R.W. & Duncan, D. R. (1997). Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. European Journal of Emergency Medicine, 4(3), 130–135.

  659. Richards, J. R., Derlet, R.W. & Duncan, D. R. (1998). Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine, 16(4), 567–573.

  660. Richards, J. R., Johnson, E. B., Stark, R.W. & Derlet, R.W. (1999). Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. American Journal of Emergency Medicine, 17(7), 681–685.

  661. Richardson, G. A., Hamel, S. C., Goldschmidt, L. & Day, N. L. (1999). Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample. Pediatrics, 104(2), e18.

  662. Riehman, K. S., Iguchi, M.Y. & Anglin, M. D. (2002). Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment. Psychology of Addictive Behaviors, 16, 333–337.

  663. Riley, S. C. E., James, C., Gregory, D., Dingle, H. & Cadger, M. (2001). Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction, 96(7), 1035–1047.

  664. Ritz, M. C., Cone, E. J. & Kuhar, M. J. (1990). Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sciences, 46(9), 635–645.

  665. Roberts, J. R. & Hedges, J. R. (1998). Clinical Procedures in Emergency Medicine (3rd ed.). Philadelphia: Saunders.

  666. Rogers, R. D., Everitt, B. J., Baldacchino, A., Blackshaw, A. J., Swainson, R., Wynne, K., Baker, N. B., Hunter, J., Carthy, T., Booker, E., London, M., Deakin, J. F., Sahakian, B. J. & Robbins, T.W. (1999). Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology, 20(4), 322–339.

  667. Rosen, C. L., Ratliff, A. F., Wolfe, R. E., Branney, S.W., Roe, E. J. & Pons, P.T. (1997).The efficacy of intravenous droperidol in the prehospital setting. Journal of Emergency Medicine, 15(1), 13–17.

  668. Rosse, R. B., Collins, J. P., McCarthy, M. F., Alim, T. N., Wyatt, R. J. & Deutsch, S. I. (1994). Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: A retrospective study. Clinical Neuropharmacology, 17(4), 359–369.

  669. Rost van Tonningen, M., Garbis, H. & Reuvers, M. (1998). Ecstasy exposure during pregnancy. Teratology, 58, 33.

  670. Rothman, R. B. & Baumann, M. H. (2002). Therapeutic and adverse actions of serotonin transporter substrates. Pharmacology and Therapeutics, 95, 73–88.

  671. Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D.V., Rice, K. C., Carroll, F. I. & Partilla, J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39(1), 32–41. Top of page

  672. Rouen, S., Dolan, K., Day, C., Topp, L., Darke, S. & Hall, W. (2002). Changes in heroin availability in Sydney, Australia in early 2001 (NDARC Technical Report No. 119). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  673. Rounsaville, B., Anton, S., Carroll, K. M., Budde, D., Prussoff, B. & Gawain, F. (1991). Psychiatric diagnoses of treatment-seeking cocaine abusers. Archives of General Psychiatry, 48, 43–51.

  674. Roy, A. (2001). Characteristics of cocaine-dependent patients who attempt suicide. American Journal of Psychiatry, 158(8), 1215–1219.

  675. Rush, C., Kelly, T., Hays, L., Baker, R. & Wooten, A. F. (2002). Acute behavioural and physiological effects of modafinil in drug abusers. Behavioural Pharmacology, 13(2), 105–115.

  676. Rush, C. R., Essman, W. D., Simpson, C. A. & Baker, R.W. (2001). Reinforcing and subjectrated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. Journal of Clinical Psychopharmacology, 21(3), 273–286.

  677. Ruttenber, A. J., McAnally, H. B. & Wetli, C.V. (1999). Cocaine-associated rhabdomyolysis and excited delirium: different stages of the same syndrome. American Journal of Forensic Medicine and Pathology, 20(2), 120–127.

  678. Rutter, M. (1985). Resilience in the face of adversity: Protective factors and resistance to psychiatric disorder. British Journal of Psychiatry, 147, 598–611.

  679. Sand, I. C., Brody, S. L., Wrenn, K. D. & Slovis, C. M. (1991). Experience with esmolol for the treatment of cocaine-associated cardiovascular complications. American Journal of Emergency Medicine, 9(2), 161–163.

  680. Satel, S. L. & Gawin, F. H. (1989). Migraine-like headache and cocaine use. Journal of the American Medical Association, 261(20), 2995–2996.

  681. Satel, S. L., Price, L. H., Palumbo, J. M., McDougle, C. J., Krystal, J. H., Gawin, F. H., Charney, D. S., Heninger, D. R. & Kleber, H. D. (1991). Clinical phenomenology, and neurobiology of cocaine abstinence: a prospective inpatient study. American Journal of Psychiatry, 148(12), 1712–1716.

  682. Sato, M., Numachi, Y. & Hamamura, T. (1992). Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia Bulletin, 18(1), 115–122.

  683. Saunders, J. B., Ward, H. & Novak, H. (1997). Guide to home detoxification. Sydney, New South Wales: Drug and Alcohol Department, Central Sydney Area Health Service.

  684. Savitz, D. A., Henderson, L., Dole, N., Herring, A., Wilkins, D. G., Rollins, D. & Thorp, J. M. Jnr., (2002). Indicators of Cocaine Exposure and Preterm Birth. Obstetrics & Gynecology, 99, 458–465.

  685. Saxena, P. R. (1995). Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacology and Therapeutics, 66(2), 339–368.

  686. Schermer, C. R. & Wisner, D. H. (1999). Methamphetamine use in trauma patients: a population-based study. Journal of the American College of Surgeons, 189(5), 442–449. Top of page

  687. Schmidt, C. J. & Taylor, V. L. (1987). Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochemical Pharmacology, 36, 4095–4102.

  688. Schmitz, J., Stotts, A., Rhoades, H. & Grabowski, J. (2001). Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addictive Behaviours, 26, 167–180.

  689. Schmitz, J. M., Averill, P., Stotts, A. L., Moeller, F. G., Rhoades, H. M. & Grabowski, J. (2001). Fluoxetine treatment of cocaine-dependent patients with depressive disorder. Drug and Alcohol Dependence, 63, 207–214.

  690. Schmitz, J. M., Stotts, A. L., Averill, P. M., Rothfleisch, J. M., Bailley, S. E., Sayre, S. L. & Grabowski, J. (2000). Cocaine dependence with and without comorbid depression: A comparison of patient characteristics. Drug and Alcohol Dependence, 60(2), 189–198.

  691. Schubiner, H., Saules, K. K., Arfken, C. L., Johansen, C.E., Schuster, C. R., Lockhart, N., Edwards, A., Donlin, J. & Pihlgren, E. (2002). Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology, 10(3), 286–294.

  692. Schumacher, J. E., Usdan, S., Milby, J. B., Wallace, D. & McNamara, C. (2000). Abstinent-contingent housing and treatment retention among crack-cocaine-dependent homeless persons. Journal of Substance Abuse Treatment, 19, 81–88.

  693. Schwartz, A. B., Janzen, D., Jones, R.T. & Boyle, W. (1989). Electrocardiographic and hemodynamic effects of intravenous cocaine in awake and anesthetized dogs. Journal of Electrocardiology, 22(2), 159–166.

  694. Screaton, G. R., Singer, M., Cairns, H. S., Thrasher, A., Sarner, M. & Cohen, S. L. (1992). Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet, 339(8794), 677–678.

  695. Secretaría Nacional Antidrogas (SENAD). (2002). Consumo de Drogas. Factores de Riesgo. Prevención. Encuesta a estudiantes de enseñanza escolar básica y secundaria de Asunción y área metropolitana. Observatoriao Paraguayo de Drogas (OPD). Presidencia de la República.

  696. Segal, D. S. & Kuczenski, R. (1997). Behavioral alterations induced by an escalating dose-binge pattern of cocaine administration. Behavioral Brain Research, 88, 251–260.

  697. Segal, D. S. & Kuczenski, R. (1999). Escalating dose-binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses. Psychopharmacology, 142, 182–192.

  698. Sekine, H., Nagao, S., Kuribara, H. & Nakahara, Y. (1997). Behavioral effects of N-cyanomethylmethamphetamine, a product derived from smoking methamphetamine with tobacco, in mice and rats. Pharmacology Biochemistry and Behavior, 57(1–2), 167–172.

  699. Sekine, H. & Nakahara, Y. (1987). Abuse of smoking methamphetamine mixed with tobacco: I. Inhalation efficiency and pyrolysis products of methamphetamine. Journal of Forensic Science, 32(5), 1271–1280.

  700. Senate Standing Committee on Social Welfare. (1977). Drug problems in Australia; An intoxicated society? Canberra, Australia: Australian Government Publishing Service.

  701. Sevarino, K. A., Oliveto, A. & Kosten, T. R. (2000). Neurobiological adaptations to psychostimulants and opiates as a basis for treatment. Annals of the New York Academy of Sciences, 909, 51–87. Top of page

  702. Shale, J. H., Shale, C. M. & Mastin, W. D. (2003). A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Journal of Clinical Psychiatry, 64(5), 500–505.

  703. Shand, F. L. & Mattick, R. P. (2001). Clients of treatment service agencies: May 2001 Census findings (National Drug Strategy Monograph No. 47). Sydney: Commonwealth Department of Health and Ageing.

  704. Shaner, A., Roberts, L. J., Eckman, T. A., Racentein, J. M., Tucker, D. E., Tsuang, J.W. & Mintz, J. (1998). Sources of diagnostic uncertainty for chronically psychotic cocaine abusers. Psychiatric Services, 49(5), 684–690.

  705. Shankaran, M., Yamamoto, B. K. & Gudelsky, G. A. (1999). Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol, 385(2–3), 103–110.

  706. Shearer, J. & Gowing, L. (submitted). Pharmacotherapies for psychostimulant problems: a review of current research.

  707. Shearer, J., Sherman, J., Wodak, A. & van Beek, I. (2002). Substitution therapy for amphetamine users. Drug and Alcohol Review Harm Reduction Digest, 21(2), 179–185.

  708. Shearer, J., Wodak, A., Mattick, R., van Beek, I., Lewis, J., Hall, W. & Dolan, K. (2001). Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction, 96(9), 1289–1296.

  709. Shearer, J., Wodak, A., van Beek, I., Mattick, R. & Lewis, J. (2003). Pilot randomised double blind placebo controlled study of dexamphetamine for cocaine dependence. Addiction, 98, 1137–1141.

  710. Shearman, L. P. & Meyer, J. S. (1999). Cocaine up-regulates norepinephrine transporter binding in the rat placenta. European Journal of Pharmacology, 386, 1–6.

  711. Sheline, Y. & Nelson, T. (1993). Patient choice: deciding between psychotropic medication and physical restraints in an emergency. Bulletin of the American Academy of Psychiatry and the Law, 21(3), 321–329.

  712. Sherman, J. P. (1990). Dexamphetamine for "speed" addiction. Medical Journal of Australia, 153, 306.

  713. Sherman, M. P. & Wheeler-Sherman, J. (2000). Cranky babies: outcomes associated with prenatal amphetamine exposure. J Perinatol, 20(7), 478.

  714. Shimosato, K. (1988). Urinary excretion of p-hydroxylated methamphetamine metabolites in man. II. Effect of alcohol intake on methamphetamine metabolism. Pharmacology Biochemistry and Behavior, 29(4), 733–740.

  715. Shoblock, J. R., Sullivan, E. B., Maisonneuve, I. M. & Glick, S. D. (2003). Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl), 165(4), 359–369.

  716. Shoobridge, J., Vincent, N., Biven, A. & Allsop, S. (2000). Using rapid assessment methodology to examine injecting drug use in an Aboriginal community. Adelaide, South Australia: National Centre for Education and Training on Addiction (NCETA)/Aboriginal Drug and Alcohol Council of SA (ADAC)/Lower Murray Nunga's Club (LMNC). Top of page

  717. Shoptaw, S., Kintaudi, P. C., Charuvastra, C. & Ling, W. (2002). A screening trial of amantadine as a medication for cocaine dependence. Drug and Alcohol Dependence, 66(3), 217–224.

  718. Shoptaw, S., Rawson, R. A., McCann, M. J. & Obert, J. L. (1994).The Matrix Model of outpatient stimulant abuse treatment: Evidence of efficacy. Journal of Addictive Diseases, 13(4), 129–141.

  719. Shulgin, A.T. (1986). The background and chemistry of MDMA. Journal of Psychoactive Drugs, 18(4), 291–304.

  720. Siegel, R. K. (1986). MDMA. Nonmedical use and intoxication. Journal of Psychoactive Drugs, 18(4), 349–354.

  721. Silvia, C. P., Jaber, M., King, G. R., Ellinwood, E. H. & Caron, M. G. (1997). Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides. Neuroscience, 76(3), 737–747.

  722. Simon, S. L., Domier, C., Carnell, J., Brethen, P., Rawson, R. & Ling, W. (2000). Cognitive impairment in individuals currently using methamphetamine. American Journal on Addictions, 9(3), 222–231.

  723. Simon, S. L., Richardson, K., Dacey, J., Glynn, S., Domier, C. P., Rawson, R. A. & Ling, W. (2002). A comparison of patterns of methamphetamine and cocaine use. Journal of Addictive Diseases, 21, 35–44.

  724. Simpson, P. J. & Eltringham, R. J. (1981). Lorazepam in intensive care. Clinical Therapeutics, 4(3), 150–163.

  725. Singer, L.T., Arendt, R., Minnes, S., Farkas, K. & Salvator, A. (2000). Neurobehavioral outcomes of cocaine-exposed infants. Neurotoxicology and Teratology, 22, 653–666.

  726. Singer, L.T., Hawkins, S., Huang, J., Davillier, M. & Baley, J. (2001). Developmental outcomes and environmental correlates of very low birthweight, cocaine-exposed infants. Early Human Development, 64, 91–103.

  727. Singer, L.T., Salvator, A., Arendt, R., Minnes, S., Farkas, K. & Kliegman, R. (2002). Effects of cocaine/polydrug exposure and maternal psychological distress on infant birth outcomes. Neurotoxicology and Teratology, 24, 127–135.

  728. Sinha, R. & Schottenfeld, R. (2001). The role of comorbidity in relapse and recovery. In F. M. Tims., C. G. Leukefeld. & J. J. Platt. (Eds.), Relapse and Recovery in Addictions (pp. 172–207). London: Yale University Press.

  729. Siris, S. G. (1985). Three cases of akathisia and "acting out". Journal of Clinical Psychiatry, 46(9), 395–397.

  730. Sloan, M. A. & Mattioni, T. A. (1992). Concurrent myocardial and cerebral infarctions after intranasal cocaine use. Stroke, 23(3), 427–430.

  731. Slotkin, T. A. (1998). Fetal nicotine or cocaine exposure: which one is worse? Journal of Pharmacology and Experimental Therapeutics, 285(3), 931–945. Top of page

  732. Smelson, D. A., McGee, C., E., Bergstein, P. & Engelhart, C. (1999). Initial validation of the Voris Cocaine Craving Scale: A preliminary report. Journal of Clinical Psychology, 55, 135–139.

  733. Smith, L., Yonekura, M. L., Wallace, T., Berman, N., Kuo, J. & Berkowitz, C. (2003). Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. Journal of Developmental & Behavioural Pediatrics, 24(1), 17–23.

  734. Smith, T. L., Volpe, F. R., Hashima, J. N. & Schuckit, M. A. (1999). Impact of a stimulant-focused enhanced program on the outcome of alcohol- and/or stimulant-dependent men. Alcoholism: Clinical and Experimental Research, 23, 1772–1779.

  735. Snodgrass, S. R. (1994). Cocaine babies: a result of multiple teratogenic influences. Journal of Child Neurology, 9(3), 227–233.

  736. Snyder, S. H. (1976). Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Psychiatric Services, 49(5), 684–690.

  737. Soar, K., Turner, J. J. D. & Parrott, A. C. (2001). Psychiatric disorders in Ecstasy (MDMA) users: A literature review focusing on personal predisposition and drug history. Human Psychopharmacology, 16(8), 641–645.

  738. Soares, B., Lima, M., Reisser, A. & Farrell, M. (2002). Dopamine agonists for cocaine dependence (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software.

  739. Sobell, L. C. & Sobell, M. B. (1992). Timeline follow-back: A technique for assessing self-reported alcohol consumption. In R. Litten & J. Allen (Eds.), Measuring Alcohol Consumption: Humana Press Inc.

  740. Soetens, E., Casaer, S., D'Hooge, R. & Hueting, J. E. (1995). Effect of amphetamine on long-term retention of verbal material. Psychopharmacology (Berl), 119(2), 155–162.

  741. Solowij, N., Hall, W. & Lee, N. (1992). Recreational MDMA use in Sydney: a profile of 'ecstasy' users and their experiences with the drug. British Journal of Addiction, 87(8), 1161–1172.

  742. Spires, M. C., Gordon, E. F., Choudhuri, M., Maldonado, E. & Chan, R. (1989). Intracranial hemorrhage in a neonate following prenatal cocaine exposure. Pediatric Neurology, 5(5), 324–326.

  743. Spitzer, R., Williams, J. & Gibbon, M. (1994). Structured Clinical Interview for DSM-IV (SCID). New York: New York Psychiatric Institute, Biometrics Research.

  744. Spooner, C., Hall, W. & Lynskey, M. (2001). Structural determinants of youth drug use (ANCD Research Paper No. 2). Sydney, New South Wales: Australian National Council on Drugs.

  745. Spooner, C., Mattick, R. & Howard, J. (1996). The nature and treatment of adolescent substance abuse (NDARC Monograph No. 26). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  746. Sprague, J. E., Everman, S. L. & Nichols, D. E. (1998). An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology, 19(3), 427–441. Top of page

  747. Srisurapanont, M., Jarusuraisin, N. & Jittawutikan, J. (1999a). Amphetamine withdrawal I: Reliability, validity and factor structure of a measure. Australian and New Zealand Journal of Psychiatry, 33, 89–93.

  748. Srisurapanont, M., Jarusuraisin, N. & Jittawutikan, J. (1999b). Amphetamine withdrawal II: A placebo-controlled, randomised, double-blind study of amineptine treatment. Australian and New Zealand Journal of Psychiatry, 33(1), 94–98.

  749. Srisurapanont, M., Jarusuraisin, N. & Kittirattanapaiboon, P. (2001).Treatment for amphetamine dependence and abuse (Cochrane Review), Epidemiology. In: The Cochrane Library, Issue 4. Oxford: Update Software.

  750. Srisurapanont, M., Jarusuraisin, N. & Kittirattanapaiboon, P. (2002).Treatment for amphetamine dependence and abuse (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software.

  751. Srisurapanont, M., Kittiratanapaiboon, P. & Jarusuraison, N. (2003).Treatment for amphetamine psychosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software.

  752. St Omer, V. E., Ali, S. F., Holson, R. R., Duhart, H. M., Scalzo, F. M. & Slikker, W., Jr. (1991). Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicology and Teratology, 13(1), 13–20.

  753. Stanislav, S.W. & Childs, A. (2000). Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain Injury, 14(3), 261–265.

  754. Stanton, M. D. & Shadish, W. R. (1997). Outcome, attrition and family/couples treatment for drug abuse: A meta-analysis and review of controlled comparative studies. Psychological Bulletin, 122, 170–191.

  755. Steele, T. D., Nichols, D. E. & Yim, G. K. (1987). Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H] monoamines into synaptosomes from different regions of rat brain. Biochemical Pharmacology, 36(14), 2297–2303.

  756. Stein, D. J. & Rink, J. (1999). Effects of "Ecstasy" blocked by serotonin reuptake inhibitors. Journal of Clinical Psychiatry, 60(7), 485.

  757. Stein, M. D., Charuvastra, A. & Anderson, B. J. (2002). Social support and zero sharing risk among hazardously drinking injection drug users. Journal of Substance Abuse Treatment, 23(3), 225–230.

  758. Sternbach, H. (1991). The serotonin syndrome. Am J Psychiatry, 148(6), 705–713.

  759. Stillman, R., Jones, R.T., Moore, D., Walker, J. & Welm, S. (1993). Improved performance 4 hours after cocaine. Psychopharmacology, 110(4), 415–420.

  760. Stitzer, M. L. & Walsh, S. L. (1997). Psychostimulant abuse: the case for combined behavioural and pharmacological treatments. Pharmacology Biochemistry and Behaviour, 57, 457–470.

  761. Strasburger, V. & Donnerstein, E. (1999). Children, adolescents and the media: Issues and solutions. The American Academy of Pediatrics, 103(1), 129–139. Top of page

  762. Stratton, S. J., Rogers, C., Brickett, K. & Gruzinski, G. (2001). Factors associated with sudden death of individuals requiring restraint for excited delirium. American Journal of Emergency Medicine, 19(3), 187–191.

  763. Streetwize Communications. (2002). On the edge

  764. Strote, J., Lee, J. E. & Wechsler, H. (2002). Increasing MDMA use among college students: Result of a national survey. Journal of Adolescent Health, 30(1), 64–72.

  765. Strother, W. N., Vorhees, C.V. & Lehman, M. N. (1998). Long-term Effects of Early Cocaine Exposure on the Light Responsiveness of the Adult Circadian Timing System. Neurotoxicology and Teratology, 20(5), 555–564.

  766. Strug, D., Hunt, D., Goldsmith, D., Lipton, D. & Spunt, B. (1985). Patterns of cocaine use among methadone clients. International Journal of the Addictions, 20(8), 1163–1175.

  767. Substance Abuse and Mental Health Services Administration (SAMHSA). (2001). Online report, from the SAMHSA website (www.samhsa.gov).

  768. Substance Abuse and Mental Health Services Administration (SAMHSA). (2002). Results from the 2001 National Household Survey on Drug Abuse: volume I. Summary of national findings (Office of Applied Studies, NHSDA Series H–17, DHHS Publication No. SMA 02–3758). Rockville, MD.

  769. Substance Abuse and Mental Health Services Administration (SAMHSA). (2003). Substance abuse prevention programs reduce high-risk youth drug use)

  770. Summers, R. L., Bradley, K., Piel, C. P. & Galli, R. L. (2001). Myocardial oxygen consumption in patients with acute cocaine intoxication. Academic Emergency Medicine, 8(5), 559.

  771. Sussman, S., Dent, C. & Stacy, A. (1999). The association of current stimulant use with demographic, substance use, violence-related, social and intrapersonal variables among high risk youth. Addictive Behaviours, 24(6), 741–748.

  772. Sutliff, R. L., Gayheart-Walsten, P. A., Snyder, D. L., Roberts, J. & Johnson, M. D. (1999). Cardiovascular Effects of Acute and Chronic Cocaine Administration in Pregnant and Nonpregnant Rabbits. Toxicology and Applied Pharmacology, 158, 278–287.

  773. Swensen, G., Ilett, K. F., Dusci, L. J., Hackett, L. P., Ong, R.T.T., Quigley, A. J., Lenton, S., Saker, R. & Caporn, J. (1993). Patterns of drug use by participants in the Western Australian methadone program, 1984–1991. The Medical Journal of Australia, 159 (20 September), 373–376.

  774. Swift, W., Copeland, J. & Hall, W. (1998). Choosing a diagnostic cut-off for cannabis dependence. Addiction, 93, 1681–1692.

  775. Swindle, R.W., Peterson, K. A., Paradise, M. J. & Moos, R. H. (1995). Measuring substance abuse program treatment orientations: The Drug and Alcohol Program Inventory. Journal of Substance Abuse Treatment, 7, 61–78.

  776. Tancer, M. E. & Johanson, C. E. (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence, 65(1), 97–101. Top of page

  777. Tashkin, D. P. (2001). Airway effects of marijuana, cocaine, and other inhaled illicit agents. Current Opinion in Pulmonary Medicine, 7(2), 43–61.

  778. Tavares, M. A., Silva, M. C., Silva-Araujo, A., Xavier, M. R. & Ali, S. F. (1996). Effects of prenatal exposure to amphetamine in the medial prefrontal cortex of the rat. International Journal of Developmental Neuroscience, 14(5), 585–596.

  779. Taylor, W. A. & Gold, M. S. (1990). Pharmacologic approaches to the treatment of cocaine dependence. Western Journal of Medicine, 152, 573–577.

  780. Teesson, M. & Burns, L. (Eds.). (2001). National comorbidity project. Canberra: Commonwealth Department of Health and Ageing.

  781. Teesson, M., Degenhardt, L. & Hall, W. (2002). Addictions. Hove, Psychology Press.

  782. Tehan, B. (1993). Ecstasy and dantrolene. British Medical Journal, 306(6870), 146.

  783. Thomas, H., Jr., Schwartz, E. & Petrilli, R. (1992). Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine, 21(4), 407–413.

  784. Topp, L. (in press). Chapter 8: Cocaine. In NCETA (Ed.), Handbook for health professionals. Adelaide: NCETA.

  785. Topp, L., Breen, C., Kaye, S. & Darke, S. (2002). NSW party drug trends 2001. Findings of the Illicit Drug Reporting System (IDRS) party drugs module. (NDARC Technical Report No. 136). Sydney: National Drug and Alcohol Research Centre.

  786. Topp, L. & Darke, S. (1997). The applicability of the dependence syndrome to amphetamine. Drug and Alcohol Dependence, 48, 113–118.

  787. Topp, L., Day, C. & Degenhardt, L. (in press). Changes in patterns of injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence.

  788. Topp, L., Degenhardt, L., Kaye, S. & Darke, S. (2002). The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system. Drug and Alcohol Review, 21, 341–348.

  789. Topp, L., Dillon, P. & Hando, J. (2002). Ecstasy: Facts and fiction. Sydney, New South Wales: National Drug and Alcohol Research Centre.

  790. Topp, L., Hall, W. & Hando, J. (1997). Is there a dependence syndrome for ecstasy? (NDARC Technical Report No. 51). Sydney, New South Wales: National Drug and Alcohol Research Centre.

  791. Topp, L., Hando, J., Dillon, P., Roche, A. & Solowij, N. (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug and Alcohol Dependence, 55(1–2), 105–115. Top of page

  792. Topp, L., Kaye, S., Bruno, R., Longo, M., Williams, P., O'Reilly, B., Fry, C., Rose, G. & Darke, S. (2002). Australian Drug Trends 2001: Findings of the Illicit Drug Reporting System (IDRS) (NDARC Monograph No. 48). Sydney: National Drug and Alcohol Research Centre.

  793. Topp, L. & Mattick, R. P. (1997a). Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction, 92(7), 839–845.

  794. Topp, L. & Mattick, R. P. (1997b).Validation of the amphetamine dependence syndrome and the SamDQ. Addiction, 92, 151–162.

  795. Topp, L., McKetin, R., Hando, J. & Dillon, P. (2001). A User's Guide to Speed. Sydney: National Drug and Alcohol Research Centre.

  796. Toumbourou, J. & Hamilton, M. (1993). Perceived client and program moderators of successful therapeutic community treatment for drug addiction. The International Journal of the Addictions, 28(11), 1127–1146.

  797. Toumbourou, J., Patton, G., Sawyer, S., Olsson, C., Web-Pullman, J., Catalano, R. & Godfrey, C. (2000). Evidence-based health promotion: Resources for planning. No 2 Adolescent Health. Melbourne, Victoria: Centre for Adolescent Health.

  798. Training and reference centre for WHO and CIDI. (1993). Composite International Diagnostic Interview. Sydney, Australia: World Health Organisation.

  799. Traub, S. J., Hoffman, R. S. & Nelson, L. S. (2002). The "Ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine. Journal of Urban Health, 79(4), 549–555.

  800. Tuchmann-Duplessis, H. (1977). Drug effects on the fetus. New York: ADIS Press.

  801. Tucker, G.T., Lennard, M. S., Ellis, S.W., Woods, H. F., Cho, A. K., Lin, L.Y., Hiratsuka, A., Schmitz, D. A. & Chu, T.Y. (1994). The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochemical Pharmacology, 47(7), 1151–1156.

  802. Tuncel, M., Wang, Z., Arbique, D., Fadel, P. J., Victor, R. G. & Vongpatanasin, W. (2002). Mechanism of the blood pressure-raising effect of cocaine in humans. Circulation, 105(9), 1054–1059.

  803. Tutton, C. & Crayton, J. (1993). Current pharmacotherapies for cocaine abuse: A review. Journal of Addictive Diseases, 12(2), 109–127.

  804. Tzschentke, T. M. (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Progress in Neurobiology, 63(3), 241–320.

  805. Ujike, H. (2002). Stimulant-induced psychosis and schizophrenia: The role of sensitization. Current Psychiatry Reports, 4, 177–184.

  806. UNICEF, WHO, World Bank & UNFPA (in press). Skills for health: skills based health education, including life skills. New York/Geneva: UNICEF/WHO/. Top of page

  807. United Nations Economic and Social Council. (2003). Report of the Secretariat: World situation with regard to drug abuse (E/CN.7/2003/4). Vienna, April 8–17, 2003: Commission on Narcotic Drugs Forty-sixth session.

  808. United Nations Office on Drugs and Crime. (2003). Global illicit drug trends 2003. New York: United Nations.

  809. Ursitti, F., Klein, J. & Koren, G. (2001). Confirmation of cocaine use during pregnancy: a critical review. Therapeutic Drug Monitoring, 23(4), 347–353.

  810. Vaiva, G., Boss, V., Bailly, D., Thomas, P., Lestavel, P. & Goudemand, M. (2001). An "accidental" acute psychosis with ecstasy use. Journal of Psychoactive Drugs, 33(1), 95–98.

  811. Vakalahi, H. F. (2001). Adolescent substance use and family based risk and protective factors: A literature review. Journal of Drug Education, 31(1), 29–46.

  812. Vale, J. A. (1997). Position statement: gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Journal of Toxicology-Clinical Toxicology, 35(7), 711–719.

  813. Vallone, D., Picetti, R. & Borrelli, E. (2000). Structure and function of dopamine receptors. Neuroscience and Biobehavioral Reviews, 24(1), 125–132.

  814. van Beek, I., Dwyer, R. & Malcolm, A. (2001). Cocaine injecting: the sharp end of drug related harm. Drug and Alcohol Review, 20(3), 333–342.

  815. van Leeuwen, A. M., Molders, J., Sterkmans, P., Mielants, P., Martens, C., Toussaint, C., Hovent, A. M., Desseilles, M. F., Koch, H., Devroye, A. & Parent, M. (1977). Droperidol in acutely agitated patients. A double-blind placebo-controlled study. Journal of Nervous and Mental Disease, 164(4), 280–283.

  816. van Tonningen, M. R., Garbis, H. & Reuvers, M. (1998). Ecstasy exposure during pregnancy. Teratology, 58, 33A.

  817. Ventura, J., Liberman, R. P., Green, M. F., Shaner, A. & Mintz, J. (1998).Training and quality assurance with Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research, 79(2), 163–173.

  818. Vincent, N., Shoobridge, J., Ask, A., Allsop, S. & Ali, R. (1998). Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug and Alcohol Review, 17(2), 187–195.

  819. Vincent, N., Shoobridge, J., Ask, A., Allsop, S. & Ali, R. (1999). Characteristics of amphetamine users seeking information, help and treatment in Adelaide, Australia. Drug and Alcohol Review, 18(1), 63–73.

  820. Viscarello, R. R., Ferguson, D. D., Nores, J. & Hobbins, J. C. (1992). Limb-body wall complex associated with cocaine abuse: further evidence of cocaine's teratogenicity. Obstetrics and Gynecology, 80(3 Pt 2), 523–526.

  821. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., Gately, S. J., Miller, E., Hitzemann, R., Ding, Y. & Logan, J. (2001). Loss dopamine transporters in methamphetamine abusers recovers with protracted abstinence. The Journal of Neuroscience, 21(23), 9414–9418. Top of page

  822. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y. S., Logan, J., Wong, C. & Miller, E. N. (2001). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry, 158(3), 377–382.

  823. Volkow, N. D., Fowler, J. S. & Ding, Y. S. (1996). Cardiotoxic properties of cocaine: Studies with positron emission tomography. In M. D. Majewkski (Ed.), Neurotoxicity and neuropathology associated with cocaine abuse (NIDA Research Monograph 163). Rockville, MD: US Department of Health and Human Services.

  824. Volkow, N. D., Wang, G. J., Fischman, M.W., Foltin, R., Fowler, J. S., Franceschi, D., Franceschi, M., Logan, J., Gatley, S. J., Wong, C., Ding, Y. S., Hitzemann, R. & Pappas, N. (2000). Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sciences, 67(12), 1507–1515.

  825. Vollenweider, F. X., Gamma, A., Liechti, M. & Huber, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology, 19(4), 241–251.

  826. Von Mayrhauser, C., Brecht, M. L. & Anglin, M. D. (2002). Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: An emerging profile. Journal of Addictive Diseases, 21, 45–60.

  827. von Sydow, K., Lieb, R., Pfister, H., Hofler, M. & Wittchen, H. U. (2002). Use, abuse and dependence of ecstasy and related drugs in adolescents — a transient phenomenon? Results from a longitudinal community study. Drug and Alcohol Dependence, 66(2), 147–159.

  828. Vuori, E., Henry, J. A., Ojanpera, I., Nieminen, R., Savolainen, T., Wahlsten, P. & Jantti, M. (2003). Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction, 98(3), 365–368.

  829. Wagner, E. & Waldron, H. (Eds.). (2001). Innovations in adolescent abuse interventions. New York: Pergamon.

  830. Waldron, H. B., Slesnick, N., Brody, J. L., Turner, C.W. & Peterson, T. R. (2001).Treatment outcomes for adolescent substance abuse at 4- and 7-month assessments. Journal of Consulting & Clinical Psychology, 69(5), 802–813.

  831. Walsh, S. L., Haberny, K. A. & Bigelow, G. E. (2000). Modulation of intravenous cocaine effects by chronic oral cocaine use in humans. Psychopharmacology, 150(4), 361–373.

  832. Wan, S. H., Matin, S. B. & Azarnoff, D. L. (1978). Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clinical Pharmacology & Therapeutics, 23(5), 585–590.

  833. Watson, D.W., Shoptaw, S., Rawson, R., Reiber, W. & Ling, W. (2002). Investigation of hypericum as a pharmacologic treatment for cocaine dependence. Drug and Alcohol Dependence, 66, S191.

  834. Watson, J. D., Ferguson, C., Hinds, C. J., Skinner, R. & Coakley, J. H. (1993). Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia, 48(12), 1057–1060.

  835. Weatherburn, D., Jones, C., Freeman, K. & Makkai, T. (2003). Supply control and harm reduction: lessons from the Australian heroin 'drought'. Addiction, 98(1), 83–91.

  836. Weber, J. E., Shofer, F. S., Larkin, G. L., Kalaria, A. S. & Hollander, J. E. (2003).Validation of a brief observation period for patients with cocaine-associated chest pain. New England Journal of Medicine, 348(6), 510–517. Top of page

  837. Weddington, W.W., Brown, B. S., Haertzen, C. A., Come, E. J., Dax, E. M., Herning, R. I. & Michaelson, B. S. (1990). Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. Archives of General Psychiatry, 47, 861–868.

  838. Weidauer, S., Nichtweiss, M., Lanfermann, H. & Zanella, F. E. (2002). Spinal cord infarction: MR imaging and clinical features in 16 cases. Neuroradiology, 44(10), 851–857.

  839. Weiner, A. L., Tilden, F. F., Jr. & McKay, C. A., Jr. (1997). Serotonin syndrome: case report and review of the literature. Connecticut Medicine, 61(11), 717–721.

  840. Weinmann, W. & Bohnert, M. (1998). Lethal monointoxication by overdosage of MDEA. Forensic Science International, 91(2), 91–101.

  841. Weir, E. (2000). Raves: A review of the culture, the drugs and the prevention of harms. Canadian Medical Association Journal, 162(13), 1843–1848.

  842. Weiss, R. D., Griffin, M. L., Najavits, L. M., Hufford, C., Kogan, J., Thompson, H. J., Albeck, J. H., Bishop, S., Daley, D. C., Mercer, D. & Siqueland, L. (1996). Self-help activities in cocaine dependent patients entering treatment: results from NIDA collaborative cocaine treatment study. Drug and Alcohol Dependence, 43(1–2), 79–86.

  843. West, R. & Gossop, M. (1994). Overview: A comparison of withdrawal symptoms from different drug classes. Addiction, 89, 1483–1489.

  844. Wexler, R. K. (2002). Evaluation and treatment of heat-related illnesses. American Family Physician, 65(11), 2307–2314.

  845. White, D. & Pitts, M. (1998). Educating young people about drugs: a systematic review. Addiction, 93, 1475–1487.

  846. White, F. J. & Kalivas, P.W. (1998). Neuroadaptations involved in amphetamine and cocaine addiction. Drug and Alcohol Dependence, 51(1–2), 141–153.

  847. White, R. (2000). Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction, 95(2), 229–238.

  848. White, V. (2001). Australian secondary students' use of over-the-counter and illicit substances in 1999 (National Drug Strategy Monograph No. 46). Canberra, Australia: Commonwealth Department of Health and Aged Care.

  849. Wickes, W. (1992). Amphetamines and other psychostimulants: A guide to the management of users. Canberra: Australian Government Publishing Service.

  850. Wickes, W. (1993). Medical aspects of psychostimulant use. In D. Burrows, B. Flaherty & M. MacAvoy (Eds.), Illicit Psychostimulant Use in Australia (pp. 31–52). Canberra: Australian Government Publishing Service.

  851. Wiegmann, D. A., Stanny, R. R., McKay, D. L., Neri, D. F. & McCardie, A. H. (1996). Methamphetamine effects on cognitive processing during extended wakefulness. International Journal of Aviation Psychology, 6(4), 379–397. Top of page

  852. Wilkins, C., Bhatta, K. & Casswell, S. (2002). The emergence of amphetamine use in New Zealand: findings from the 1998 and 2001 National Drug Surveys. New Zealand Medical Journal, 22, 115–116.

  853. Williams, H., Dratcu, L., Taylor, R., Roberts, M. & Oyefeso, A. (1998). "Saturday night fever": ecstasy related problems in a London accident and emergency department. Journal of Accident & Emergency Medicine, 15(5), 322–326.

  854. Williams, M.T., Vorhees, C.V., Boon, F., Saber, A. J. & Cain, D. P. (2002). Methamphetamine exposure from postnatal day 11 to 20 causes impairments in both behavioral strategies and spatial learning in adult rats. Brain Research, 958(2), 312–321.

  855. Williamson, S., Gossop, M., Powis, B., Griffiths, P., Fountain, J. & Strang, J. (1997). Adverse effects of stimulant drugs in a community sample of drug users. Drug and Alcohol Dependence, 44, 87–94.

  856. Wilson, J.T., Brown, R. D., Cherek, D. R., Dailey, J.W., Hilman, B., Jobe, P. C., Manno, B. R., Manno, J. E., Redetzki, H. M. & Stewart, J. J. (1980). Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clinical Pharmacokinetics, 5(1), 1–66.

  857. Winstock, A. R., Griffiths, P. & Stewart, D. (2001). Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug and Alcohol Dependence, 64(1), 9–17.

  858. Winters, K. C. (1999).Treating adolescents with substance use disorders: an overview of practice issues and treatment outcomes. Substance Abuse, 20(4), 203–225.

  859. Winters, K. C., Stinchfield, R. D., Opland, E., Weller, C. & Latimer, W.W. (2000).The effectiveness of the Minnesota Model approach in the treatment of adolescent drug abusers. Addiction, 95, 601–612.

  860. Withers, N.W., Pulvirenti, L., Koob, G. F. & Gillin, J. C. (1995). Cocaine abuse and dependence. Journal of Clinical Psychopharmacology, 15(1), 63–78.

  861. Wittchten, H. U. (1994). Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review. Journal of Psychiatric Research, 28, 57–84.

  862. Won, L., Bubula, N. & Heller, A. (2002). Fetal exposure to (+-)-methylenedioxymethamphetamine in utero enhances the development and metabolism of serotonergic neurons in three-dimensional reaggregate tissue culture. Developmental Brain Research, 137, 67–73.

  863. World Health Organisation. (1992). The international classification of mental and behavioural disorders. Geneva: WHO.

  864. World Health Organisation. (1994). Life skills education in schools. Geneva: WHO.

  865. World Health Organisation. (1997). Amphetamine type stimulants.A report from the WHO meeting on amphetamines, MDMA and other psychostimulants. Geneva: WHO.

  866. World Health Organisation. (1999). Programming for adolescent health and development. Report of a WHO/UNFPA/UNICEF study group on programming for adolescent health. Geneva: WHO. Top of page

  867. World Health Organisation. (2001). Global consultation on adolescent friendly health services.A consensus statement. 7–9 March 2001, Geneva: Department of Child and Adolescent Health, WHO.

  868. World Health Organisation. (2002). Broadening the horizon. Balancing protection and risk for adolescents. Geneva: Department of Child and Adolescent Health, WHO.

  869. Wright, S. & Klee, H. (1999). A profile of amphetamine users who present to treatment services and do not return. Drugs: Education, Prevention and Policy, 6(2), 227–241.

  870. Wright, S. & Klee, H. (2001). Violent crime, aggression and amphetamine: What are the implications for drug treatment services? Drugs: Education, Prevention and Policy, 8(1), 73–90.

  871. Wright, S., Klee, H. & Reid, P. (1999). Attitudes of amphetamine users towards treatment services. Drugs: Education, Prevention and Policy, 6(1), 71–86.

  872. Wu, D., Otton, S.V., Inaba, T., Kalow, W. & Sellers, E. M. (1997). Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology, 53(11), 1605–1612.

  873. Yakubu, M. A., Pourcyrous, M., Randolph, M. M., Blaho, K. E., Mandrell, T. D., Bada, H. S. & Leffler, C.W. (2002). Consequences of maternal cocaine on cerebral microvascular functions in piglets. Brain Research, 947(174–181).

  874. Yamamoto, Y., Yamamoto, K., Fukui, Y. & Kurishita, A. (1992).Teratogenic effects of methamphetamine in mice. Japanese Journal of Legal Medicine, 46, 126–131.

  875. Yen, D. J., Wang, S. J., Ju, T. H., Chen, C. C., Liao, K. K., Fuh, J. L. & Hu, H. H. (1994). Stroke associated with methamphetamine inhalation. European Neurology, 34(1), 16–22.

  876. Yuan, J., Callahan, B.T., McCann, U. D. & Ricaurte, G. A. (2001). Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. Journal of Neurochemistry, 2001, 1338–1347.

  877. Yui, K., Goto, K., Ikemoto, S., Nishijima, K., Yoshino, T. & Ishiguro, T. (2001). Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis. Drug and Alcohol Dependence, 64, 133–142.

  878. Yui, K., Ikemoto, S., Ishiguro, T. & Goto, K. (2000). Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia. In S. F. Ali (Ed.), Neurobiological Mechanisms of Drugs of Abuse: Cocaine, Ibogaine, and Substituted Amphetamines (Vol. 914, pp. 1–12). New York: The New York Academy of Sciences.

  879. Zemishlany, Z., Aizenberg, D. & Weizman, A. (2001). Subjective effects of MDMA ('Ecstasy') on human sexual function. European Psychiatry, 16(2), 127–130.

  880. Zhimin, L., Xianxiang, L. & Jiaqi, C. (in press). Recent situation of drug abuse in China. Report of the multicity epidemiology work group. (International Monograph Series No. 16). Penang: Centre for Drug Research — Universiti Sains Malaysia.

  881. Zimberg, S. (1999). A dual diagnosis typology to improve diagnosis and treatment of dual disorder patients. Journal of Psychoactive Drugs, 31(3), 47–51. Top of page

  882. Zuckerman, B., Frank, D. A., Hingson, R., Amaro, H., Levenson, S. M., Kayne, H., Parker, S., Vinci, R., Aboagye, K. & Fried, L. E. (1989). Effects of maternal marijuana and cocaine use on fetal growth. New England Journal of Medicine, 320(12), 762–768.
Top of page